_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,baselinedec,e1,e2,rel-type,sent_id,sentence,term1,term2
789214323,9/16/2015 13:25:36,1739507453,9/16/2015 13:25:15,false,neodev,1,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",of or,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 13:48:35,1739516631,9/16/2015 13:48:08,false,neodev,1,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]
[PART_OF]",of or effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:01:07,1739520636,9/16/2015 14:00:03,false,neodev,1,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]
[PART_OF]",of or effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:12:38,1739524719,9/16/2015 14:12:18,false,clixsense,1,6340330,USA,NY,Canajoharie,67.248.115.74,[PREVENTS],[PREVENTS],modify the production of acid,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:13:26,1739525007,9/16/2015 14:13:05,false,neodev,1,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]
[PART_OF]",of or effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:24:02,1739528649,9/16/2015 14:23:40,false,neodev,1,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]
[PART_OF]",of or effective,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:28:56,1739530376,9/16/2015 14:28:00,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,[PREVENTS],[PREVENTS],modify the production of acid,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:47:25,1739537353,9/16/2015 14:47:01,false,neodev,1,18881135,CAN,ON,Ajax,99.243.87.224,[PREVENTS],[PREVENTS],NON FLUORIDE AGENTS modify production of PLAQUE,na,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 14:53:02,1739539540,9/16/2015 14:52:47,false,bitcoinget,1,20311164,NLD,09,Utrecht,84.105.54.251,[PREVENTS],[PREVENTS],modify the production,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 15:09:20,1739546254,9/16/2015 15:08:10,false,clixsense,1,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 15:09:21,1739546256,9/16/2015 15:08:40,false,prodege,1,22031444,GBR,F2,Gosport,92.24.223.243,[PREVENTS],[PREVENTS],which modify the production of acid in,N/a,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 15:10:05,1739546587,9/16/2015 15:09:30,false,instagc,1,22981457,CAN,ON,Ottawa,67.69.8.122,[PREVENTS],[PREVENTS],promise for use effective anticaries systems.,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 15:15:11,1739548810,9/16/2015 15:14:06,false,neodev,1,23017572,USA,CA,Santa Ana,67.215.241.20,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",which modify the production of acid,n/a,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 15:18:38,1739550391,9/16/2015 15:17:33,false,prodege,1,34294822,USA,TX,Allen,99.7.230.126,[TREATS],[TREATS],effective anticaries systems.,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214323,9/16/2015 15:19:12,1739550742,9/16/2015 15:17:40,false,neodev,1,32499893,USA,CA,San Jose,23.27.248.207,[MANIFESTATION],[MANIFESTATION],NON FLUORIDE AGENTS PLAQUE,N/A,74,15,80,79,34,RO-may_prevent,820369-FS1,"In the future, NON FLUORIDE AGENTS which modify the production of acid in PLAQUE  either antimicrobially, biochemically, or directly  appear to have the most promise for use in topical products and may prove to be effective anticaries systems.",PLAQUE,NON FLUORIDE AGENTS
789214324,9/16/2015 10:53:03,1739465555,9/16/2015 10:52:13,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,[SYMPTOM],[SYMPTOM],resistant sensitive revealed.,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 10:53:04,1739465562,9/16/2015 10:52:41,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 10:59:26,1739467433,9/16/2015 10:58:38,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were revealed.,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:00:52,1739467986,9/16/2015 11:00:30,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],resistant,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:20:18,1739473258,9/16/2015 11:20:01,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[LOCATION] [MANIFESTATION] [CONTRAINDICATES] [ASSOCIATED_WITH] [SIDE_EFFECT] [IS_A] [NONE],"[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[NONE]",In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MIn patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (M,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (M,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:20:22,1739473281,9/16/2015 11:19:54,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],resistant to,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:21:54,1739473599,9/16/2015 11:21:40,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],resistant,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:22:41,1739473755,9/16/2015 11:22:30,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:26:09,1739474372,9/16/2015 11:25:45,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],RIFAMPICIN,none,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:39:22,1739477531,9/16/2015 11:38:18,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PART_OF],[PART_OF],detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:41:30,1739478101,9/16/2015 11:40:17,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],resistant to,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 11:50:29,1739480394,9/16/2015 11:50:05,false,neodev,1,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [ASSOCIATED_WITH] [IS_A] [CAUSES] [NONE],"[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[TREATS],N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 12:22:11,1739487867,9/16/2015 12:19:49,false,neodev,1,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],resistant to were revealed.,n/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 12:35:18,1739491239,9/16/2015 12:34:57,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,[CONTRAINDICATES],[CONTRAINDICATES],resistant to,n/a,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214324,9/16/2015 12:41:27,1739492997,9/16/2015 12:40:24,false,neodev,1,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,30,80,42,41,90,RO-may_prevent,820205-FS1,In patients with new detected TUBERCULOSIS 23.5% MBT resistant to isoniazid and RIFAMPICIN (MDR) and sensitive to fluoroquinolones were revealed.,TUBERCULOSIS,RIFAMPICIN
789214325,9/16/2015 12:44:48,1739494059,9/16/2015 12:44:19,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were observed during acute period,n/a,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 12:54:55,1739497470,9/16/2015 12:54:27,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 13:08:23,1739501887,9/16/2015 13:08:06,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 13:15:37,1739504346,9/16/2015 13:15:06,false,elite,1.0,28548715,USA,"","",38.95.109.38,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the high levels of,n/a,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 13:19:08,1739505509,9/16/2015 13:18:46,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 13:41:26,1739514321,9/16/2015 13:41:11,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 13:52:45,1739517820,9/16/2015 13:52:24,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:03:16,1739521373,9/16/2015 14:02:02,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,[IS_A] [PART_OF] [ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]","SERUM HEPATITIS high levels of HBSAG were observed during acute period of disease,",n/a,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:05:04,1739521893,9/16/2015 14:04:47,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:05:40,1739522081,9/16/2015 14:05:11,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[CAUSES],[CAUSES],high levels,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:10:55,1739524171,9/16/2015 14:10:31,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[MANIFESTATION],[MANIFESTATION],were observed,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:17:17,1739526254,9/16/2015 14:17:01,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF],[PART_OF],of of of,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:29:04,1739530421,9/16/2015 14:27:41,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",high levels,n/a,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:38:34,1739533940,9/16/2015 14:37:11,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],SERUM HEPATITIS high levels of HBSAG were observed,na,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214325,9/16/2015 14:47:26,1739537359,9/16/2015 14:47:07,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were observed,N/A,3,38,18,17,43,RO-may_prevent,820327-FS1,"In SERUM HEPATITIS the high levels of HBSAG and HBcAb were observed during the acute period of the disease, while the content of HBsAb did not exceed the normal level.",SERUM HEPATITIS,HBSAG
789214326,9/16/2015 12:37:19,1739491822,9/16/2015 12:36:57,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 12:44:18,1739493925,9/16/2015 12:43:56,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Effect of fenofibrate,n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 12:54:23,1739497291,9/16/2015 12:53:31,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [ASSOCIATED_WITH] [SIDE_EFFECT] [IS_A],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",of a with Effect with of a a,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 13:08:03,1739501803,9/16/2015 13:07:25,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [IS_A] [ASSOCIATED_WITH] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",of a with Effect of of of,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 13:15:04,1739504143,9/16/2015 13:14:44,false,elite,1.0,28548715,USA,"","",38.95.109.38,[SIDE_EFFECT],[SIDE_EFFECT],Effect of fenofibrate,n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 13:18:43,1739505364,9/16/2015 13:18:12,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",of with Effect of of,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 13:41:08,1739514251,9/16/2015 13:40:30,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of a with,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 13:52:21,1739517693,9/16/2015 13:51:49,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [IS_A] [SIDE_EFFECT],"[SIDE_EFFECT]
[IS_A]
[PART_OF]",of a with Effect of,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:02:02,1739520892,9/16/2015 13:59:33,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","placebo controlled, prevention of type 2 diabetes double blind trial INSULIN SECRETION before diagnosis of TYPE 2 DIABETES",n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:04:44,1739521789,9/16/2015 14:04:05,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of a with of of an a,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:05:10,1739521920,9/16/2015 14:04:19,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[SYMPTOM],[SYMPTOM],"insulin sensitivity,",N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:10:30,1739524006,9/16/2015 14:08:28,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],controlled trial,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:12:14,1739524603,9/16/2015 14:12:07,false,prodege,1,12656479,CAN,NB,Fredericton,198.164.157.91,[CAUSES],[CAUSES],"sensitivity,",N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:16:59,1739526185,9/16/2015 14:16:04,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [ASSOCIATED_WITH] [IS_A] [SIDE_EFFECT],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",of a with Effect of with of a of of a,N/A,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214326,9/16/2015 14:27:38,1739529914,9/16/2015 14:26:00,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],an analysis evaluated for cardiovascular outcomes in oral agent combination therapy,n/a,577,391,444,591,408,RO-may_treat,820094-FS1,"placebo controlled, multicentre trial  Voglibose for prevention of type 2 diabetes mellitus: a randomised, double blind trial in Japanese individuals with impaired glucose tolerance  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial  Trajectories of glycaemia, insulin sensitivity, and INSULIN SECRETION before diagnosis of type 2 diabetes: an analysis from the Whitehall II study  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for TYPE 2 DIABETES (RECORD): a multicentre.",TYPE 2 DIABETES,INSULIN SECRETION
789214327,9/16/2015 09:31:03,1739441911,9/16/2015 09:30:49,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],to receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 09:35:55,1739443081,9/16/2015 09:34:55,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 09:42:15,1739444740,9/16/2015 09:40:46,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,"A more suitable relationship would be ""is treated with"".",42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 09:48:47,1739446223,9/16/2015 09:48:33,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 09:53:15,1739447404,9/16/2015 09:52:47,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],receive cimetidine,n/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 09:56:58,1739448485,9/16/2015 09:56:08,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],receive,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:02:31,1739450313,9/16/2015 10:02:07,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"study,",N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:02:54,1739450444,9/16/2015 10:01:09,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:05:01,1739451221,9/16/2015 10:04:39,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],DUODENAL receive CIMETIDINE 800 mg daily.,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:06:50,1739451828,9/16/2015 10:06:29,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],to receive,N/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:08:56,1739452481,9/16/2015 10:08:25,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[LOCATION],[LOCATION],DUODENAL ULCER CIMETIDINE,prevent,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:09:45,1739452693,9/16/2015 10:09:28,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,n/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:12:13,1739453358,9/16/2015 10:11:55,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:30:11,1739458895,9/16/2015 10:29:53,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,N/A,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214327,9/16/2015 10:35:58,1739460558,9/16/2015 10:33:37,false,elite,1.0,30782237,GBR,H9,London,164.143.240.34,[TREATS],[TREATS],receive,n/a,42,165,56,55,175,RO-may_prevent,820293-FS1,"In a double blind study, 35 patients with DUODENAL ULCER diagnosed by endoscopy were randomly assigned to receive cimetidine 800 mg daily and 38 patients to receive CIMETIDINE 800 mg plus sulpiride 200 mg daily.",DUODENAL ULCER,CIMETIDINE
789214328,9/16/2015 09:36:02,1739443098,9/16/2015 09:35:47,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],efficacious for,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 09:49:18,1739446341,9/16/2015 09:48:37,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 09:52:37,1739447202,9/16/2015 09:52:04,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],for,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 09:55:13,1739448025,9/16/2015 09:54:42,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,The statement is a question and does not provide any useful information.,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 09:56:41,1739448403,9/16/2015 09:56:31,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],really efficacious,n/a,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:06:45,1739451794,9/16/2015 10:05:55,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:10:11,1739452802,9/16/2015 10:09:21,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[OTHER],[OTHER],Questions,question,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:11:09,1739453124,9/16/2015 10:10:30,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],ACETAMINOPHEN efficacious for OSTEOARTHRITIS PAIN,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:14:30,1739454043,9/16/2015 10:14:16,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],efficacious,n/a,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:14:47,1739454121,9/16/2015 10:14:32,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],efficacious for,N/a,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:17:17,1739455108,9/16/2015 10:16:24,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],ACETAMINOPHEN OSTEOARTHRITIS PAIN,prevent,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:17:26,1739455134,9/16/2015 10:17:00,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:20:31,1739456020,9/16/2015 10:18:35,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:33:55,1739460024,9/16/2015 10:33:39,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],efficacious,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214328,9/16/2015 10:38:14,1739461120,9/16/2015 10:37:42,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],efficacious for,N/A,68,31,87,86,44,RO-may_treat,820096-FS1,Frequently Asked Questions  Is ACETAMINOPHEN really efficacious for OSTEOARTHRITIS PAIN,OSTEOARTHRITIS PAIN,ACETAMINOPHEN
789214329,9/16/2015 10:59:12,1739467360,9/16/2015 10:58:44,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:08:35,1739470114,9/16/2015 11:08:18,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:24:17,1739474005,9/16/2015 11:24:01,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[MANIFESTATION] [SYMPTOM] [CAUSES] [PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[NONE]",Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystroph,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystroph,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:25:32,1739474267,9/16/2015 11:25:16,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:30:40,1739475450,9/16/2015 11:30:25,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HYPERGLYCEMIA,none,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:48:04,1739479810,9/16/2015 11:47:33,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],due to INSULIN RESISTANCE,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:48:26,1739479859,9/16/2015 11:47:17,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[SIDE_EFFECT],[SIDE_EFFECT],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:48:51,1739479994,9/16/2015 11:48:31,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],due to,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 11:56:38,1739481772,9/16/2015 11:56:10,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [PART_OF] [ASSOCIATED_WITH] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",[TREATS],N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 12:29:33,1739489532,9/16/2015 12:29:06,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SIDE_EFFECT],[SIDE_EFFECT],may occur with,n/a,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 12:39:52,1739492513,9/16/2015 12:39:31,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CONTRAINDICATES],[CONTRAINDICATES],due to RESISTANCE,n/a,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 12:46:47,1739494843,9/16/2015 12:46:31,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 12:54:06,1739497228,9/16/2015 12:52:58,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[CAUSES],[CAUSES],HYPERGLYCEMIA due to INSULIN RESISTANCE,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 13:02:26,1739499746,9/16/2015 13:02:13,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214329,9/16/2015 13:08:50,1739501995,9/16/2015 13:08:16,false,elite,1.0,28548715,USA,"","",38.95.109.38,[SYMPTOM],[SYMPTOM],Hyperlipidemia HYPERGLYCEMIA,n/a,19,40,32,31,58,RO-may_treat,820052-FS1,Hyperlipidemia and HYPERGLYCEMIA due to INSULIN RESISTANCE and nonalcoholic steatohepatitis may occur with lipodystrophy.,HYPERGLYCEMIA,INSULIN RESISTANCE
789214330,9/16/2015 11:13:34,1739471375,9/16/2015 11:13:19,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],reduction,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 11:26:33,1739474438,9/16/2015 11:26:17,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [TREATS] [CAUSES] [ASSOCIATED_WITH] [CONTRAINDICATES] [SYMPTOM] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]","Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.","Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 11:30:32,1739475397,9/16/2015 11:30:10,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],significant,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 11:36:04,1739476673,9/16/2015 11:35:50,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],GLYCERYL TRINITRATE,none,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 11:53:32,1739481045,9/16/2015 11:53:03,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],significant reduction,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 11:57:09,1739481851,9/16/2015 11:56:13,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],significant reduction in and,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 12:00:39,1739482735,9/16/2015 12:00:13,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [IS_A] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[IS_A]
[OTHER]
[NONE]",[TREATS],N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 12:34:52,1739491097,9/16/2015 12:34:23,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[CAUSES],[CAUSES],caused a,n/a,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 12:42:21,1739493290,9/16/2015 12:42:08,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],reduction,n/a,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 12:51:17,1739496241,9/16/2015 12:50:50,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[CAUSES] [IS_A] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]
[IS_A]",caused a with,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 13:03:38,1739500106,9/16/2015 13:01:57,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",caused a significant reduction in GLYCERYL TRINITRATE with angina pectoris and ANGINA,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 13:05:35,1739500902,9/16/2015 13:05:14,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[CAUSES] [IS_A] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]
[IS_A]",caused a with,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 13:12:55,1739503467,9/16/2015 13:12:43,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],caused,n/a,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 13:16:24,1739504680,9/16/2015 13:16:13,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",caused a,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214330,9/16/2015 13:39:47,1739513833,9/16/2015 13:39:30,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[IS_A] [CAUSES],"[CAUSES]
[IS_A]",caused a,N/A,145,65,151,150,84,RO-may_prevent,820175-FS1,"Both verapamil and propranolol caused a significant reduction in GLYCERYL TRINITRATE tablet consumption, days with angina pectoris and in severe ANGINA attacks compared to placebo.",ANGINA,GLYCERYL TRINITRATE
789214331,9/16/2015 11:12:13,1739471029,9/16/2015 11:11:12,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],induced,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:25:09,1739474225,9/16/2015 11:24:53,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [CAUSES] [SYMPTOM] [PART_OF] [SIDE_EFFECT] [CONTRAINDICATES] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]",We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induc,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induc,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:26:41,1739474443,9/16/2015 11:26:20,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[MANIFESTATION],[MANIFESTATION],combined,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:31:32,1739475584,9/16/2015 11:31:17,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DISOPYRAMIDE,none,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:50:16,1739480346,9/16/2015 11:49:52,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],induced by combined use of clarithromycin and DISOPYRAMIDE,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:50:45,1739480436,9/16/2015 11:50:17,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],induced by use of,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:52:16,1739480746,9/16/2015 11:51:19,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[CAUSES],[CAUSES],induced by,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 11:58:13,1739482129,9/16/2015 11:57:47,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CONTRAINDICATES] [SYMPTOM] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 12:31:21,1739489967,9/16/2015 12:30:53,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],by combined use of,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 12:40:55,1739492810,9/16/2015 12:40:39,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CAUSES],[CAUSES],induced by,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 12:48:04,1739495225,9/16/2015 12:47:42,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]
[PART_OF]",a by of,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 12:56:02,1739497838,9/16/2015 12:55:06,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[CAUSES],[CAUSES],TDP VENTRICULAR TACHYCARDIA induced by use clarithromycin and DISOPYRAMIDE,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 13:03:46,1739500153,9/16/2015 13:03:13,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",by of,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 13:11:05,1739502782,9/16/2015 13:10:46,false,elite,1.0,28548715,USA,"","",38.95.109.38,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TACHYCARDIA DISOPYRAMIDE,n/a,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214331,9/16/2015 13:12:58,1739503486,9/16/2015 13:12:12,false,clixsense,1,19638651,USA,SC,Summerville,174.107.73.211,[SIDE_EFFECT],[SIDE_EFFECT],induced by,N/A,44,118,71,70,130,RO-may_prevent,820374-FS1,We report a 76 year old woman who developed TDP VENTRICULAR TACHYCARDIA induced by combined use of clarithromycin and DISOPYRAMIDE,TDP VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
789214332,9/16/2015 13:11:44,1739502990,9/16/2015 13:11:21,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[PART_OF]",during of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 13:18:25,1739505295,9/16/2015 13:18:13,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],"case,",n/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 13:21:57,1739506339,9/16/2015 13:21:41,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 13:44:59,1739515562,9/16/2015 13:44:42,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF],[PART_OF],of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 13:56:19,1739519076,9/16/2015 13:56:04,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:09:26,1739523681,9/16/2015 14:09:00,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],took,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:09:26,1739523685,9/16/2015 14:09:09,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:20:38,1739527468,9/16/2015 14:20:15,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF],[PART_OF],of,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:24:16,1739528772,9/16/2015 14:24:00,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CAUSES],[CAUSES],leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:42:57,1739535666,9/16/2015 14:42:38,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],METOPROLOL leads to VENTRICULAR TACHYCARDIA,na,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:50:05,1739538495,9/16/2015 14:49:54,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[CAUSES],[CAUSES],leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:56:56,1739541257,9/16/2015 14:56:11,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],METOPROLOL VENTRICULAR TACHYCARDIA,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:58:17,1739541824,9/16/2015 14:57:33,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[CAUSES],[CAUSES],which leads to,N/A,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 14:59:01,1739542091,9/16/2015 14:57:43,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214332,9/16/2015 15:04:21,1739544433,9/16/2015 15:03:35,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",which leads to,N/a,124,51,147,146,61,RO-may_treat,820132-FS1,"The patient took in 120 mgs prajmaline and 600 mgs METOPROLOL during the day of the case, which leads to cardiogenic shock, VENTRICULAR TACHYCARDIA and ventricular fibrillation.",VENTRICULAR TACHYCARDIA,METOPROLOL
789214333,9/16/2015 09:36:35,1739443220,9/16/2015 09:36:03,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CONTRAINDICATES],[CONTRAINDICATES],Do not use,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 09:50:08,1739446528,9/16/2015 09:49:18,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CONTRAINDICATES],[CONTRAINDICATES],Do not use,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 09:52:52,1739447339,9/16/2015 09:52:39,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 09:56:14,1739448275,9/16/2015 09:55:15,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,"The sentence has a negative connotation, it does not provide any positive information or relationship.",107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 09:58:52,1739449060,9/16/2015 09:56:42,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],screening test for primary,n/a,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:07:59,1739452160,9/16/2015 10:06:46,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:10:49,1739452990,9/16/2015 10:10:13,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:11:50,1739453272,9/16/2015 10:11:09,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SYMPTOM],[SYMPTOM],SPIRONOLACTONE screening test primary HYPERALDOSTERONISM,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:15:02,1739454218,9/16/2015 10:14:31,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,n/a,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:17:42,1739455212,9/16/2015 10:17:28,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:17:58,1739455323,9/16/2015 10:17:19,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],SPIRONOLACTONE HYPERALDOSTERONISM,prevent,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:22:12,1739456592,9/16/2015 10:20:32,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:34:27,1739460196,9/16/2015 10:33:58,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:38:59,1739461357,9/16/2015 10:38:15,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214333,9/16/2015 10:39:03,1739461362,9/16/2015 10:38:27,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening test,N/A,107,60,126,124,74,RO-may_treat,820055-FS1," Do not use response to an aldosterone antagonist, such as SPIRONOLACTONE as a screening test for primary HYPERALDOSTERONISM",HYPERALDOSTERONISM,SPIRONOLACTONE
789214334,9/16/2015 12:45:04,1739494174,9/16/2015 12:44:48,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was found to have,n/a,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 12:55:26,1739497648,9/16/2015 12:54:59,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",with other,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 13:08:42,1739501952,9/16/2015 13:08:25,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",with other,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 13:16:05,1739504564,9/16/2015 13:15:38,false,elite,1.0,28548715,USA,"","",38.95.109.38,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Among 4 Asian patients with coexisting,n/a,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 13:19:24,1739505591,9/16/2015 13:19:10,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 13:41:56,1739514475,9/16/2015 13:41:29,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 13:53:34,1739518087,9/16/2015 13:53:21,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:05:19,1739521952,9/16/2015 14:05:07,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:06:12,1739522275,9/16/2015 14:03:21,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[ASSOCIATED_WITH] [IS_A] [PART_OF],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",patients with coexisting ANTI HCV AND HBSAG 1 was to have SERUM HEPATITIS B VIRAL DNA,n/a,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:06:23,1739522345,9/16/2015 14:05:41,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],coexisting,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:12:23,1739524619,9/16/2015 14:10:56,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[SYMPTOM],[SYMPTOM],found to have,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:17:41,1739526396,9/16/2015 14:17:20,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:30:17,1739530833,9/16/2015 14:29:08,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[CAUSES] [MANIFESTATION] [SYMPTOM] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",found to have,n/a,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:39:40,1739534322,9/16/2015 14:38:35,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],coexisting ANTI HCV AND HBSAG 1 found to have SERUM HEPATITIS B VIRAL DNA,na,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214334,9/16/2015 14:43:41,1739535917,9/16/2015 14:43:29,false,neodev,1,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],none,n/a,78,39,94,104,59,RO-may_prevent,820177-FS1,Among 4 Asian patients with coexisting ANTI HCV AND HBSAG 1 was found to have SERUM HEPATITIS B VIRAL DNA and the other 3 had hepatitis C viral RNA.,SERUM HEPATITIS B VIRAL DNA,ANTI HCV AND HBSAG 1
789214335,9/16/2015 10:49:40,1739464549,9/16/2015 10:49:02,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[OTHER],[OTHER],or any ingredient,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 10:51:10,1739465019,9/16/2015 10:49:25,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 10:54:43,1739465995,9/16/2015 10:53:19,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],ingredient in the formulations.,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 10:56:38,1739466530,9/16/2015 10:55:17,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],commercially available,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 10:58:35,1739467179,9/16/2015 10:58:17,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:11:55,1739470895,9/16/2015 11:11:44,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],WILLEBRAND,NONE,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:15:00,1739471837,9/16/2015 11:13:28,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Contraindications,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:19:04,1739472911,9/16/2015 11:18:48,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[MANIFESTATION]
[NONE]",ontraindications  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,ontraindications  Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:20:49,1739473374,9/16/2015 11:20:36,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SIDE_EFFECT],[SIDE_EFFECT],or,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:21:22,1739473503,9/16/2015 11:21:11,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],or,n/a,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:24:38,1739474130,9/16/2015 11:24:02,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ANTIHEMOPHILIC FACTOR,none,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:25:22,1739474248,9/16/2015 11:25:12,false,elite,1.0,33798502,USA,DE,"",108.59.8.208,[PREVENTS],[PREVENTS],Cautions,It makes sense,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:35:39,1739476596,9/16/2015 11:35:12,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CONTRAINDICATES],[CONTRAINDICATES],Contraindications,N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:44:02,1739478798,9/16/2015 11:43:25,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[NONE],[NONE],N/a,Two non-related terms.,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214335,9/16/2015 11:48:37,1739479933,9/16/2015 11:48:12,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [ASSOCIATED_WITH] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",[TREATS],N/A,111,86,125,144,107,RO-may_treat,820012-FS1,133  Cautions  Contraindications    Known hypersensitivity to commercially available ANTIHEMOPHILIC FACTOR or VON WILLEBRAND FACTOR PREPARATIONS or any ingredient in the formulations.,VON WILLEBRAND FACTOR PREPARATIONS,ANTIHEMOPHILIC FACTOR
789214336,9/16/2015 11:13:18,1739471297,9/16/2015 11:13:02,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 11:26:15,1739474395,9/16/2015 11:26:00,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION] [ASSOCIATED_WITH] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 11:30:09,1739475294,9/16/2015 11:29:52,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 11:35:49,1739476664,9/16/2015 11:35:37,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],(IDDM 24,none,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 11:53:01,1739480935,9/16/2015 11:52:23,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DEPENDENT DIABETICS insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 11:56:10,1739481681,9/16/2015 11:55:31,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],and,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 12:00:10,1739482632,9/16/2015 11:59:44,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [ASSOCIATED_WITH] [CONTRAINDICATES] [NONE],"[CAUSES]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",[TREATS],N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 12:34:22,1739490967,9/16/2015 12:33:29,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were requiring,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 12:42:07,1739493255,9/16/2015 12:41:53,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],requiring,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 12:50:47,1739496054,9/16/2015 12:49:17,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[SYMPTOM],[SYMPTOM],(IDDM (NIDDM.,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 13:01:55,1739499549,9/16/2015 12:59:55,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[OTHER],[OTHER],10 were insulin DEPENDENT DIABETICS and 66 NON INSULIN DEPENDENT DIABETICS,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 13:05:11,1739500753,9/16/2015 13:04:52,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[OTHER],[OTHER],10 (IDDM,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 13:12:41,1739503354,9/16/2015 13:12:21,false,elite,1.0,28548715,USA,"","",38.95.109.38,[PART_OF],[PART_OF],DEPENDENT DIABETICS INSULIN DEPENDENT DIABETICS,n/a,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 13:16:10,1739504594,9/16/2015 13:15:23,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[OTHER],[OTHER],10 (IDDM 24 66 (NIDDM.,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214336,9/16/2015 13:36:46,1739511684,9/16/2015 13:36:05,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[OTHER],[OTHER],10 (IDDM DIABETICS,N/A,16,70,41,40,101,RO-may_treat,820134-FS1,10 were insulin DEPENDENT DIABETICS (IDDM 24 insulin requiring and 66 NON INSULIN DEPENDENT DIABETICS (NIDDM.,DEPENDENT DIABETICS (IDDM,NON INSULIN DEPENDENT DIABETICS
789214337,9/16/2015 13:10:56,1739502753,9/16/2015 13:10:38,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS] [ASSOCIATED_WITH] [IS_A] [PART_OF],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment with a of of,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 13:17:57,1739505121,9/16/2015 13:17:44,false,elite,1.0,28548715,USA,"","",38.95.109.38,[TREATS],[TREATS],Treatment,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 13:21:16,1739506094,9/16/2015 13:20:57,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS] [ASSOCIATED_WITH] [PART_OF],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]",Treatment with of,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 13:44:15,1739515304,9/16/2015 13:43:40,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[TREATS] [ASSOCIATED_WITH] [IS_A] [PART_OF],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment with a of,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 13:55:36,1739518745,9/16/2015 13:55:15,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [ASSOCIATED_WITH] [IS_A],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]",Treatment with a,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:08:36,1739523273,9/16/2015 14:08:22,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],Treatment,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:08:46,1739523349,9/16/2015 14:08:21,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [ASSOCIATED_WITH] [PART_OF] [IS_A],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment with a of of of,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:12:58,1739524838,9/16/2015 14:12:18,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],Treatment with RANITIDINE for DUODENAL ULCER,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:19:39,1739527129,9/16/2015 14:19:16,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[TREATS] [ASSOCIATED_WITH] [IS_A] [PART_OF],"[TREATS]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",Treatment with a of of of,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:22:47,1739528247,9/16/2015 14:19:57,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],Treatment with,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:37:39,1739533566,9/16/2015 14:37:02,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],Treatment with,n/a,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:42:16,1739535378,9/16/2015 14:41:48,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],Treatment with RANITIDINE healed DUODENAL ULCER patients,na,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:49:22,1739538213,9/16/2015 14:49:13,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],healed,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:54:27,1739540192,9/16/2015 14:53:15,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[TREATS],[TREATS],RANITIDINE DUODENAL ULCER,N/A,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214337,9/16/2015 14:57:41,1739541550,9/16/2015 14:56:31,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,69,15,83,82,25,RO-may_prevent,820211-FS1,Treatment with RANITIDINE for a maximum of six weeks healed 97.1% of DUODENAL ULCER patients (172 out of 177) and 96.5% of gastric ulcer patients (77 out of 81.,DUODENAL ULCER,RANITIDINE
789214338,9/16/2015 10:57:18,1739466747,9/16/2015 10:56:48,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:07:02,1739469726,9/16/2015 11:06:46,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:23:24,1739473916,9/16/2015 11:23:10,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [LOCATION] [SYMPTOM] [SIDE_EFFECT] [CONTRAINDICATES] [NONE],"[PREVENTS]
[LOCATION]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]","he author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.","he author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:24:40,1739474131,9/16/2015 11:24:25,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:25:20,1739474247,9/16/2015 11:25:11,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],treated,n/a,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:29:46,1739475204,9/16/2015 11:29:33,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],RANITIDINE,none,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:43:55,1739478761,9/16/2015 11:42:59,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],efficacy of in patients treated in,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:45:41,1739479163,9/16/2015 11:44:56,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compares the efficacy ranitidine 300 mg and RANITIDINE 150 MG,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:46:59,1739479504,9/16/2015 11:46:39,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 11:55:10,1739481481,9/16/2015 11:54:51,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[IS_A] [ASSOCIATED_WITH] [NONE],"[ASSOCIATED_WITH]
[IS_A]
[NONE]",[TREATS],N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 12:27:46,1739489111,9/16/2015 12:27:16,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treated in,n/a,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 12:38:44,1739492184,9/16/2015 12:38:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],"bedtime dose,",n/a,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 12:45:44,1739494374,9/16/2015 12:45:24,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A] [TREATS],"[TREATS]
[IS_A]",a treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 12:50:50,1739496060,9/16/2015 12:50:04,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],RANITIDINE in DUODENAL ULCER patients treated in two Italian multicentre trials.,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214338,9/16/2015 13:01:24,1739499371,9/16/2015 13:01:05,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[SIDE_EFFECT] [TREATS] [PART_OF] [IS_A],"[TREATS]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",efficacy of a treated,N/A,122,84,136,135,101,RO-may_prevent,820334-FS1,"The author compares the efficacy of ranitidine 300 mg in a single bedtime dose, and RANITIDINE 150 MG twice daily, in 509 DUODENAL ULCER patients treated in two Italian multicentre trials.",DUODENAL ULCER,RANITIDINE 150 MG
789214339,9/16/2015 13:10:35,1739502627,9/16/2015 13:10:13,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 13:17:43,1739505056,9/16/2015 13:17:13,false,elite,1.0,28548715,USA,"","",38.95.109.38,[PART_OF],[PART_OF],vein thrombophlebitis occurring independently from,n/a,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 13:20:53,1739506007,9/16/2015 13:20:35,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 13:43:37,1739515054,9/16/2015 13:43:12,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF],[PART_OF],of treatment,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 13:55:11,1739518602,9/16/2015 13:54:48,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of treatment of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:08:19,1739523145,9/16/2015 14:07:59,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:08:21,1739523160,9/16/2015 14:07:46,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurrence,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:12:16,1739524612,9/16/2015 14:10:07,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",management of from HEPARIN INDUCED THROMBOCYTOPENIA PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,n/a,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:19:14,1739526886,9/16/2015 14:18:49,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF],[PART_OF],of treatment of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:19:56,1739527237,9/16/2015 14:17:58,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[IS_A],[IS_A],In contrast to,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:36:59,1739533322,9/16/2015 14:34:45,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[MANIFESTATION],[MANIFESTATION],occurrence of,n/a,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:41:47,1739535235,9/16/2015 14:41:11,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],HEPARIN INDUCED THROMBOCYTOPENIA occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,na,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:49:12,1739538144,9/16/2015 14:48:56,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SYMPTOM],[SYMPTOM],occurrence of,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:53:13,1739539589,9/16/2015 14:51:51,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[TREATS] [CAUSES],"[TREATS]
[CAUSES]",PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation thrombocytopenia,N/A,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214339,9/16/2015 14:53:43,1739539845,9/16/2015 14:52:02,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,212,119,88,250,151,RO-may_treat,820136-FS1,In contrast to difficulties in the management of puerperal ovarian vein thrombophlebitis  occurring independently from HEPARIN INDUCED THROMBOCYTOPENIA (surgical treatment necessary in most cases)  occurrence of PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS in relation to heparin induced thrombocytopenia seems to response better to fibrinolysis and anticoagulation.,PUERPERAL OVARIAN VEIN THROMBOPHLEBITIS,HEPARIN INDUCED THROMBOCYTOPENIA
789214340,9/16/2015 11:13:01,1739471228,9/16/2015 11:12:46,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],relief,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 11:25:58,1739474333,9/16/2015 11:25:44,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS] [LOCATION] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL A,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 11:29:50,1739475214,9/16/2015 11:28:23,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CONTRAINDICATES],[CONTRAINDICATES],compare,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 11:32:16,1739475730,9/16/2015 11:32:00,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],LIDOCAINE,none,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 11:52:20,1739480756,9/16/2015 11:51:16,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],measured using a PAIN VISUAL ANALOG SCALE,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 11:55:27,1739481551,9/16/2015 11:54:09,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],in the relief of episiotomy pain measured using a,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 11:59:42,1739482466,9/16/2015 11:59:10,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [IS_A] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[IS_A]
[NONE]",[TREATS],N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 12:33:28,1739490687,9/16/2015 12:32:20,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],using a,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 12:41:52,1739493163,9/16/2015 12:41:32,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],relief of pain,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 12:49:14,1739495547,9/16/2015 12:48:49,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 12:59:53,1739498872,9/16/2015 12:58:33,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",2% LIDOCAINE in episiotomy pain measured using a PAIN VISUAL ANALOG SCALE,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 13:04:49,1739500651,9/16/2015 13:04:24,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[SIDE_EFFECT] [PART_OF] [IS_A],"[SIDE_EFFECT]
[IS_A]
[PART_OF]",efficacy of of a,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 13:12:19,1739503237,9/16/2015 13:11:52,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],in the relief of episiotomy pain,n/a,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 13:17:24,1739504987,9/16/2015 13:17:06,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[SIDE_EFFECT] [PART_OF],"[SIDE_EFFECT]
[PART_OF]",efficacy of of of,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214340,9/16/2015 13:39:27,1739513781,9/16/2015 13:39:10,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[SIDE_EFFECT] [PART_OF],"[SIDE_EFFECT]
[PART_OF]",efficacy of of of,N/A,179,119,183,202,128,RO-may_prevent,820379-FS1,The aim was to compare the efficacy of transcutaneous electrical nerve stimulation (TENS) and local infiltration of 2% LIDOCAINE in the relief of episiotomy pain measured using a PAIN VISUAL ANALOG SCALE (VAS.,PAIN VISUAL ANALOG SCALE,LIDOCAINE
789214341,9/16/2015 09:31:26,1739441963,9/16/2015 09:31:04,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],in the management of,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 09:37:06,1739443355,9/16/2015 09:35:57,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],doses,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 09:43:13,1739444952,9/16/2015 09:42:16,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,There was no positive relationship between these words.,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 09:49:03,1739446283,9/16/2015 09:48:48,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],effect,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 09:53:42,1739447550,9/16/2015 09:53:22,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],management of,n/a,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 09:58:25,1739448906,9/16/2015 09:56:59,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],without effect,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:03:12,1739450564,9/16/2015 10:02:33,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],effect,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:05:04,1739451220,9/16/2015 10:02:55,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:05:25,1739451307,9/16/2015 10:05:02,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],BUPIVACAINE management of PAIN,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:07:25,1739451985,9/16/2015 10:06:51,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[OTHER],[OTHER],was without effect,N/a,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:09:34,1739452659,9/16/2015 10:08:58,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],BUPIVACAINE PAIN,prevent,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:10:18,1739452807,9/16/2015 10:09:47,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[OTHER],[OTHER],without,n/a,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:12:32,1739453439,9/16/2015 10:12:15,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],effect,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:30:32,1739458966,9/16/2015 10:30:14,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],safe doses,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214341,9/16/2015 10:35:16,1739460356,9/16/2015 10:34:11,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],effect in the management,N/A,98,46,102,101,57,RO-may_prevent,820217-FS1,instillation of therapeutically safe doses of BUPIVACAINE was without effect in the management of PAIN postoperative pulmonary dysfunction and the stress response in this group of patients.,PAIN,BUPIVACAINE
789214342,9/16/2015 11:14:23,1739471659,9/16/2015 11:14:10,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],lower,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 11:32:13,1739475725,9/16/2015 11:31:57,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],lower,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 11:37:04,1739476907,9/16/2015 11:36:49,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[PREVENTS],[PREVENTS],HYPOTHYROIDISM,none,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 11:55:59,1739481655,9/16/2015 11:54:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[OTHER],[OTHER],glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 11:59:38,1739482462,9/16/2015 11:58:42,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],groups group,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 12:01:58,1739483016,9/16/2015 12:01:36,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[IS_A]
[NONE]",[TREATS],N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 12:36:31,1739491597,9/16/2015 12:35:55,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],control,n/a,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 12:43:44,1739493760,9/16/2015 12:43:14,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],group were higher,n/a,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 12:53:04,1739496806,9/16/2015 12:52:41,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 13:07:00,1739501519,9/16/2015 13:06:28,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 13:14:25,1739503901,9/16/2015 13:14:01,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],levels were lower in renal,n/a,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 13:17:47,1739505068,9/16/2015 13:17:28,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 13:40:04,1739513915,9/16/2015 13:39:50,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 13:51:07,1739517349,9/16/2015 13:50:41,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of,N/A,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214342,9/16/2015 13:58:36,1739519867,9/16/2015 13:56:18,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of HYPOTHYROIDISM THYROXINE ADMINISTRATION groups,n/a,148,165,162,188,174,RO-may_prevent,820218-FS1,Both malondialdehyde (MDA) and glutathione (GSH) levels were lower in renal and testicular tissues of the hypothyroidism group than the control and HYPOTHYROIDISM + THYROXINE ADMINISTRATION groups and the levels in hypothyroidism + THYROXINE administration group were higher than those in the control and hypothyroidism groups (p.,HYPOTHYROIDISM + THYROXINE ADMINISTRATION,THYROXINE
789214343,9/16/2015 11:12:29,1739471083,9/16/2015 11:12:15,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:25:23,1739474256,9/16/2015 11:25:12,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [MANIFESTATION] [ASSOCIATED_WITH] [PART_OF] [OTHER] [SIDE_EFFECT] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]
[OTHER]
[NONE]",Will giving ACETAMINOPHEN prevent the PAIN of t,Will giving ACETAMINOPHEN prevent the PAIN of t,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:27:58,1739474802,9/16/2015 11:26:42,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:31:45,1739475654,9/16/2015 11:31:33,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],ACETAMINOPHEN,none,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:50:41,1739480421,9/16/2015 11:50:17,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[NONE],[NONE],N/A,It's a question,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:51:21,1739480570,9/16/2015 11:50:46,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:52:34,1739480821,9/16/2015 11:52:19,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 11:58:41,1739482218,9/16/2015 11:58:15,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[IS_A] [CONTRAINDICATES] [CAUSES] [PREVENTS] [OTHER] [NONE],"[PREVENTS]
[CAUSES]
[CONTRAINDICATES]
[IS_A]
[OTHER]
[NONE]",[TREATS],N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 12:31:38,1739490063,9/16/2015 12:31:23,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PREVENTS],[PREVENTS],prevent of,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 12:41:08,1739492897,9/16/2015 12:40:56,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],prevent,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 12:48:20,1739495283,9/16/2015 12:48:07,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 12:57:07,1739498150,9/16/2015 12:56:04,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[PREVENTS],[PREVENTS],ACETAMINOPHEN prevent the PAIN,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 13:04:01,1739500218,9/16/2015 13:03:51,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 13:11:28,1739502871,9/16/2015 13:11:07,false,elite,1.0,28548715,USA,"","",38.95.109.38,[PREVENTS],[PREVENTS],prevent,n/a,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214343,9/16/2015 13:14:01,1739503817,9/16/2015 13:12:59,false,clixsense,1.0,19638651,USA,SC,Summerville,174.107.73.211,[PREVENTS],[PREVENTS],prevent,N/A,38,12,42,41,25,RO-may_treat,820062-FS1,Will giving ACETAMINOPHEN prevent the PAIN of the immunization.,PAIN,ACETAMINOPHEN
789214344,9/16/2015 13:11:18,1739502838,9/16/2015 13:10:59,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS] [PART_OF] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",treatment of is of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 13:18:12,1739505255,9/16/2015 13:17:58,false,elite,1.0,28548715,USA,"","",38.95.109.38,[TREATS],[TREATS],are used in the treatment,n/a,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 13:21:38,1739506274,9/16/2015 13:21:20,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 13:44:40,1739515469,9/16/2015 13:44:18,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 13:56:00,1739518909,9/16/2015 13:55:39,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:09:00,1739523457,9/16/2015 14:08:36,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],treatment,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:09:07,1739523536,9/16/2015 14:08:49,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [PART_OF] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",treatment of is of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:20:13,1739527331,9/16/2015 14:19:42,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [TREATS] [IS_A],"[TREATS]
[IS_A]
[PART_OF]",treatment of is of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:23:59,1739528647,9/16/2015 14:22:48,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:38:29,1739533912,9/16/2015 14:37:42,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],used in the treatment,n/a,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:42:37,1739535531,9/16/2015 14:42:17,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],DIGITALIS COMPOUNDS used in treatment of CONGESTIVE HEART FAILURE,na,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:49:53,1739538408,9/16/2015 14:49:23,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],treatment,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:56:08,1739540953,9/16/2015 14:54:29,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[PREVENTS],[PREVENTS],DIGITALIS COMPOUNDS CONGESTIVE HEART FAILURE,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:56:29,1739541079,9/16/2015 14:53:45,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214344,9/16/2015 14:57:32,1739541502,9/16/2015 14:54:52,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[TREATS],[TREATS],treatment of,N/A,49,0,73,72,19,RO-may_prevent,820260-FS1,"DIGITALIS COMPOUNDS are used in the treatment of CONGESTIVE HEART FAILURE as positive inotropic agents; their action is mainly due to the inhibition of Na(+),K(+) ATPase.",CONGESTIVE HEART FAILURE,DIGITALIS COMPOUNDS
789214345,9/16/2015 10:56:46,1739466570,9/16/2015 10:56:32,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DRUG,Drug,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:06:45,1739469687,9/16/2015 11:06:23,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[OTHER],[OTHER],levels,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:23:08,1739473863,9/16/2015 11:22:52,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[CAUSES] [LOCATION] [MANIFESTATION] [IS_A] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[CAUSES]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]","ow that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic","ow that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic",23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:24:23,1739474046,9/16/2015 11:24:08,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],eliminated,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:25:11,1739474229,9/16/2015 11:24:56,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],without,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:29:33,1739475165,9/16/2015 11:29:12,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],CHLOROQUINE,none,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:42:55,1739478473,9/16/2015 11:41:27,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",2 doses of,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:44:53,1739479006,9/16/2015 11:44:17,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],parasites can be eliminated,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:46:38,1739479424,9/16/2015 11:46:05,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],doses given,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 11:54:49,1739481378,9/16/2015 11:54:24,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[PREVENTS] [IS_A] [CONTRAINDICATES] [MANIFESTATION] [SYMPTOM] [NONE],"[PREVENTS]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[IS_A]
[NONE]",[TREATS],N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 12:27:15,1739488993,9/16/2015 12:26:38,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],are given,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 12:38:26,1739492116,9/16/2015 12:38:11,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],doses of,n/a,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 12:45:20,1739494289,9/16/2015 12:44:55,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",of a with of,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 12:49:58,1739495758,9/16/2015 12:49:03,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],DRUG RESISTANT MALARIA parasites can be eliminated from the body without toxic levels of CHLOROQUINE,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214345,9/16/2015 13:01:02,1739499216,9/16/2015 13:00:44,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with an,N/A,23,208,45,44,219,RO-may_prevent,820261-FS1,"We show that, even for DRUG RESISTANT MALARIA if 2 doses of chloroquine are given to a patient with an interval of some 10 days between them, parasites can be eliminated from the body without toxic levels of CHLOROQUINE being reached.",DRUG RESISTANT MALARIA,CHLOROQUINE
789214346,9/16/2015 09:35:46,1739443028,9/16/2015 09:35:17,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[PART_OF],[PART_OF],HEPATITIS B SEROLOGY IN SERUM (HBSAG,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 09:48:36,1739446212,9/16/2015 09:47:08,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],antibody,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 09:52:02,1739447031,9/16/2015 09:51:47,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],because,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 09:54:40,1739447858,9/16/2015 09:52:56,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[IS_A],[IS_A],HEPATITIS B SEROLOGY IN SERUM (HBSAG,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 09:56:30,1739448327,9/16/2015 09:56:15,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATITIS B SEROLOGY IN SERUM,n/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:05:52,1739451472,9/16/2015 10:05:15,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],testing for,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:09:19,1739452586,9/16/2015 10:08:54,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:10:29,1739452932,9/16/2015 10:09:31,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SYMPTOM],[SYMPTOM],testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:14:15,1739453961,9/16/2015 10:13:49,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,n/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:14:31,1739454037,9/16/2015 10:13:52,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[IS_A],[IS_A],HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg),N/a,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:16:22,1739454711,9/16/2015 10:15:27,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEPATITIS B SEROLOGY IN SERUM (HBSAG,cause,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:16:58,1739454968,9/16/2015 10:16:43,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],because,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:18:35,1739455490,9/16/2015 10:16:59,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:33:36,1739459890,9/16/2015 10:33:23,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],because,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214346,9/16/2015 10:41:42,1739462158,9/16/2015 10:40:49,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,N/A,107,138,118,135,143,RO-may_prevent,820184-FS1,Forty five blood recipients were considered susceptible to hepatitis B virus infection because testing for HEPATITIS B SEROLOGY IN SERUM (HBSAG antibody to HBsAg and antibody to HBcAg) was negative before being transfused.,HEPATITIS B SEROLOGY IN SERUM,HBSAG
789214347,9/16/2015 09:41:15,1739444485,9/16/2015 09:40:48,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES] [CONTRAINDICATES],"[CAUSES]
[CONTRAINDICATES]",antagonism,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 09:56:23,1739448300,9/16/2015 09:56:10,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 09:58:39,1739448983,9/16/2015 09:57:49,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],observed in studies,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:15:33,1739454402,9/16/2015 10:15:16,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigate,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:16:18,1739454680,9/16/2015 10:15:54,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],(RIFAMPICIN observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:16:19,1739454691,9/16/2015 10:15:42,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[SYMPTOM],[SYMPTOM],observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:18:38,1739455509,9/16/2015 10:18:18,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],doses,n/a,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:22:12,1739456572,9/16/2015 10:21:48,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],combination observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:25:13,1739457461,9/16/2015 10:24:30,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,prevent,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:36:37,1739460702,9/16/2015 10:35:09,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:39:36,1739461525,9/16/2015 10:39:07,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:45:50,1739463295,9/16/2015 10:45:04,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],investigate the antagonism between,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:46:16,1739463458,9/16/2015 10:44:58,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:46:39,1739463597,9/16/2015 10:45:39,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG] [OTHER],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]",observed in,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214347,9/16/2015 10:52:37,1739465427,9/16/2015 10:50:58,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],antimicrobial activity,N/A,128,67,155,167,78,RO-may_prevent,820262-FS1,To investigate the antagonism between isoniazid (INH) and rifampin (RIFAMPICIN (RIF) pyrazinamide (PZA) combination observed in MYCOBACTERIUM TUBERCULOSIS INFECTED MICE extensive pharmacokinetic studies of INH were performed and followed by experiments to assess the impact of increasing doses of INH on the antimicrobial activity of RIF PZA combination.,MYCOBACTERIUM TUBERCULOSIS INFECTED MICE,(RIFAMPICIN
789214348,9/16/2015 10:56:30,1739466499,9/16/2015 10:56:09,false,elite,1,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:06:21,1739469536,9/16/2015 11:05:51,false,elite,1,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:22:50,1739473778,9/16/2015 11:22:34,false,neodev,1,33228343,USA,DE,Wilmington,199.115.115.207,[TREATS] [PREVENTS] [MANIFESTATION] [LOCATION] [CAUSES] [ASSOCIATED_WITH] [IS_A] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",im of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,im of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:24:06,1739473992,9/16/2015 11:23:51,false,elite,1,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:24:55,1739474168,9/16/2015 11:24:44,false,bitcoinget,1,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],treatment,n/a,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:29:11,1739475058,9/16/2015 11:28:51,false,zoombucks,1,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],ONDANSETRON,none,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:41:23,1739478089,9/16/2015 11:40:23,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:44:15,1739478822,9/16/2015 11:43:45,false,gifthunterclub,1,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:46:03,1739479229,9/16/2015 11:45:45,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 11:54:22,1739481280,9/16/2015 11:53:55,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[ASSOCIATED_WITH] [SYMPTOM] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",[TREATS],N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 12:26:36,1739488834,9/16/2015 12:26:03,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment of,n/a,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 12:38:10,1739492063,9/16/2015 12:37:49,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment of,n/a,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 12:44:52,1739494084,9/16/2015 12:44:33,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of of of,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 12:49:01,1739495485,9/16/2015 12:48:03,false,neodev,1,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],ONDANSETRON the treatment of OPIOID INDUCED NAUSEA AND EMESIS,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214348,9/16/2015 13:00:42,1739499123,9/16/2015 13:00:20,false,neodev,1,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [SIDE_EFFECT] [TREATS],"[TREATS]
[SIDE_EFFECT]
[PART_OF]",of efficacy of treatment,N/A,135,76,157,166,87,RO-may_prevent,820186-FS1,The aim of this study was to compare the anti emetic efficacy and safety of ONDANSETRON placebo and metoclopramide in the treatment of OPIOID INDUCED NAUSEA AND EMESIS (OIE) in cancer patients.,OPIOID INDUCED NAUSEA AND EMESIS,ONDANSETRON
789214349,9/16/2015 09:38:43,1739443832,9/16/2015 09:38:27,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],dosage adjustment,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 09:55:35,1739448123,9/16/2015 09:55:21,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CONTRAINDICATES],[CONTRAINDICATES],required;,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 09:56:01,1739448192,9/16/2015 09:55:32,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],dosage,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:13:43,1739453734,9/16/2015 10:12:52,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",may occur,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:13:59,1739453823,9/16/2015 10:13:29,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[CAUSES],[CAUSES],occur,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:14:58,1739454185,9/16/2015 10:14:22,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[CAUSES],[CAUSES],INSULIN or oral hypoglycemics HYPERGLYCEMIA,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:17:28,1739455157,9/16/2015 10:17:04,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],may occur,n/a,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:20:36,1739456056,9/16/2015 10:20:13,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],dosage adjustment,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:23:07,1739456831,9/16/2015 10:22:22,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],INSULIN HYPERGLYCEMIA,treat,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:32:10,1739459492,9/16/2015 10:30:57,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:37:43,1739461019,9/16/2015 10:37:27,false,elite,1.0,30659677,USA,"","",162.252.172.126,[OTHER],[OTHER],required;,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:43:34,1739462598,9/16/2015 10:43:03,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[CAUSES],[CAUSES],diabetes,Causes,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:44:05,1739462808,9/16/2015 10:43:17,false,neodev,1,11382239,AUS,02,Strathfield,60.241.129.81,[PREVENTS],[PREVENTS],dosage adjustment,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:44:06,1739462809,9/16/2015 10:43:38,false,elite,1.0,30782237,GBR,H9,London,164.143.240.34,[TREATS],[TREATS],required;,n/a,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214349,9/16/2015 10:44:32,1739462938,9/16/2015 10:43:11,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],dosage adjustment,N/A,110,63,18,122,70,RO-may_treat,820021-FS1,"109  Hyperglycemia  In diabetic patients, dosage adjustment of INSULIN or oral hypoglycemics may be required; HYPERGLYCEMIA may occur and latent diabetes mellitus may become evident.",HYPERGLYCEMIA,INSULIN
789214350,9/16/2015 09:42:37,1739444815,9/16/2015 09:41:59,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 09:57:19,1739448554,9/16/2015 09:56:45,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],above,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:00:42,1739449696,9/16/2015 09:59:24,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],categorised into three groups:,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:16:36,1739454808,9/16/2015 10:16:07,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],levels,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:17:09,1739455065,9/16/2015 10:16:49,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Isolated TESTOSTERONE below above normal range (ENDOCRINE HYPOGONADISM,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:17:36,1739455190,9/16/2015 10:17:04,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],above normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:19:15,1739455720,9/16/2015 10:18:58,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:22:59,1739456813,9/16/2015 10:22:31,false,elite,1.0,30659754,USA,"","",162.250.145.204,[LOCATION],[LOCATION],within,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:26:40,1739457858,9/16/2015 10:26:10,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],TESTOSTERONE (ENDOCRINE HYPOGONADISM,treat,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:39:59,1739461657,9/16/2015 10:38:02,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:41:29,1739462113,9/16/2015 10:40:44,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],within normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:46:56,1739463682,9/16/2015 10:46:21,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],categorised into three groups:,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:47:30,1739463874,9/16/2015 10:46:51,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:49:29,1739464457,9/16/2015 10:48:13,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[CAUSES],[CAUSES],above normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214350,9/16/2015 10:53:41,1739465764,9/16/2015 10:52:39,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],below normal range,N/A,266,218,289,288,230,RO-may_treat,820143-FS1,"Gonadal hormone levels were categorised into three groups: 1: All gonadal hormones within normal range (normal), 2: Isolated elevated FSH, with LH, SHBG and testosterone within normal range (exocrine hypogonadism), 3: TESTOSTERONE below and/or LH above normal range (ENDOCRINE HYPOGONADISM",(ENDOCRINE HYPOGONADISM,TESTOSTERONE
789214351,9/16/2015 10:53:43,1739465765,9/16/2015 10:53:26,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 10:54:37,1739465968,9/16/2015 10:53:45,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],recommended by,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:00:24,1739467821,9/16/2015 10:59:51,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[OTHER] [TREATS],"[TREATS]
[OTHER]",recommended by,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:01:25,1739468190,9/16/2015 11:01:10,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:20:58,1739473417,9/16/2015 11:20:40,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[TREATS] [PREVENTS] [LOCATION] [SIDE_EFFECT] [IS_A] [ASSOCIATED_WITH] [CONTRAINDICATES] [MANIFESTATION] [NONE],"[TREATS]
[PREVENTS]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[NONE]","hildren with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg","hildren with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg",159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:22:27,1739473707,9/16/2015 11:22:12,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],assigned to treatment,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:23:15,1739473885,9/16/2015 11:22:54,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],recommended,n/a,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:26:44,1739474450,9/16/2015 11:26:29,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],CHLOROQUINE,none,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:27:28,1739474642,9/16/2015 11:25:53,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],recommended by,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:40:42,1739477924,9/16/2015 11:39:50,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[OTHER],[OTHER],CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:42:23,1739478352,9/16/2015 11:42:02,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment with,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 11:51:26,1739480602,9/16/2015 11:50:59,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[DIAGNOSE_BY_TEST_OR_DRUG] [IS_A] [SYMPTOM] [ASSOCIATED_WITH] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[TREATS],N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 12:23:16,1739488067,9/16/2015 12:22:47,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment with,n/a,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 12:35:48,1739491383,9/16/2015 12:35:33,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],recommended,n/a,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214351,9/16/2015 12:42:21,1739493297,9/16/2015 12:41:31,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [SYMPTOM] [PART_OF] [IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",with symptomatic with a of by or with a,N/A,159,125,175,182,136,RO-may_prevent,820343-FS1,"Children with symptomatic malaria in Bissau, Guinea Bissau were randomly assigned to treatment with a 25 mg/kg total dose of CHLOROQUINE as recommended by the NATIONAL MALARIA PROGRAM or with a higher total dose of 50 mg/kg.",NATIONAL MALARIA PROGRAM,CHLOROQUINE
789214352,9/16/2015 09:32:05,1739442133,9/16/2015 09:31:42,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Treat:,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 09:38:58,1739443873,9/16/2015 09:38:00,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 09:45:00,1739445309,9/16/2015 09:43:58,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[OTHER],[OTHER],Treat:,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 09:49:36,1739446407,9/16/2015 09:49:20,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 09:54:17,1739447723,9/16/2015 09:53:56,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],with,n/a,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:00:38,1739449665,9/16/2015 09:59:04,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:04:30,1739450960,9/16/2015 10:03:43,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],Treat:,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:06:16,1739451592,9/16/2015 10:05:51,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],DEPRESSION with TRICYCLIC ANTIDEPRESSANTS newer agents,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:07:45,1739452076,9/16/2015 10:05:57,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:09:21,1739452596,9/16/2015 10:08:50,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],Treat:,N/a,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:10:57,1739453032,9/16/2015 10:10:19,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TRICYCLIC ANTIDEPRESSANTS,you,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:11:03,1739453073,9/16/2015 10:10:37,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],therapy,n/a,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:13:07,1739453597,9/16/2015 10:12:52,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:31:13,1739459187,9/16/2015 10:30:56,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214352,9/16/2015 10:36:16,1739460620,9/16/2015 10:35:16,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],DEPRESSION with TRICYCLIC ANTIDEPRESSANTS,N/A,410,426,420,419,451,RO-may_treat,820025-FS1,"BC]  Specific recommendation:  Treat:  Sialorrhea with amitriptyline, glycopyrrolate, or transdermal scopolamine patches; if sialorrhea is refractory, consider radiation therapy of the salivary glands or botulinum toxin injections of the salivary glands  Thick mucus with propranolol or metoprolol  Pseudobulbar affect or emotional lability with dextromethorphan/quinidine, amitriptyline, or fluvoxamine  DEPRESSION with TRICYCLIC ANTIDEPRESSANTS such as amitriptyline or newer agents such as sertraline  Anxiety with anxiolytics such as benzodiazepines  Insomnia with noninvasive ventilation, pain management, antidepressants, or hypnotics, depending on.",DEPRESSION,TRICYCLIC ANTIDEPRESSANTS
789214353,9/16/2015 11:08:54,1739470219,9/16/2015 11:08:36,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],use full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:24:34,1739474122,9/16/2015 11:24:19,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [TREATS] [MANIFESTATION] [CONTRAINDICATES] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[NONE]","his sentence:  However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin ti","his sentence:

However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin ti",14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:25:49,1739474314,9/16/2015 11:25:33,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:30:56,1739475470,9/16/2015 11:30:41,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEPARIN,none,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:48:37,1739479930,9/16/2015 11:48:06,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],use full dose HEPARIN,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:49:21,1739480160,9/16/2015 11:48:51,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",necessary to use,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:49:44,1739480255,9/16/2015 11:48:30,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],use full dose,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 11:57:10,1739481855,9/16/2015 11:56:41,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[LOCATION] [MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[NONE]",[TREATS],N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 12:30:20,1739489716,9/16/2015 12:29:34,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],to use,n/a,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 12:40:06,1739492549,9/16/2015 12:39:52,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],use full dose,n/a,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 12:47:17,1739495029,9/16/2015 12:46:51,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",is by with,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 12:54:29,1739497317,9/16/2015 12:54:08,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],"VENOUS THROMBOSIS has already occurred, use full dose HEPARIN",N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 13:02:50,1739499803,9/16/2015 13:02:29,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",is by with of,N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 13:09:35,1739502292,9/16/2015 13:08:51,false,elite,1.0,28548715,USA,"","",38.95.109.38,[TREATS] [CAUSES],"[TREATS]
[CAUSES]","occurred,",n/a,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214353,9/16/2015 13:11:28,1739502870,9/16/2015 13:10:53,false,fusioncash,1.0,21457135,USA,FL,Orlando,71.42.61.239,[TREATS],[TREATS],"full dose continuous intravenous route,",N/A,14,87,31,30,94,RO-may_prevent,820388-FS1,"However, once VENOUS THROMBOSIS has already occurred, it is necessary to use full dose HEPARIN preferably by the continuous intravenous route, with maintenance of the partial thromboplastin time (PTT) at 1 1/2 times the control at all times.",VENOUS THROMBOSIS,HEPARIN
789214354,9/16/2015 12:36:55,1739491706,9/16/2015 12:36:32,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment with,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 12:43:55,1739493819,9/16/2015 12:43:45,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 12:53:27,1739496918,9/16/2015 12:53:08,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 13:07:22,1739501650,9/16/2015 13:07:02,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 13:14:42,1739504016,9/16/2015 13:14:26,false,elite,1.0,28548715,USA,"","",38.95.109.38,[TREATS],[TREATS],treatment,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 13:18:09,1739505217,9/16/2015 13:17:50,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 13:40:28,1739514017,9/16/2015 13:40:06,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 13:51:46,1739517525,9/16/2015 13:51:11,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 13:59:32,1739520130,9/16/2015 13:58:36,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],Eighty patients with DUODENAL ULCER were allocated to treatment with CIMETIDINE,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 14:04:03,1739521610,9/16/2015 14:03:15,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 14:04:18,1739521687,9/16/2015 14:02:23,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],treatment,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 14:08:27,1739523241,9/16/2015 14:08:01,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment with,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 14:12:06,1739524543,9/16/2015 14:11:43,false,prodege,1.0,12656479,CAN,NB,Fredericton,198.164.157.91,[PREVENTS],[PREVENTS],allocated,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 14:16:01,1739525867,9/16/2015 14:15:33,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[ASSOCIATED_WITH] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with treatment with or,N/A,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214354,9/16/2015 14:25:55,1739529301,9/16/2015 14:24:51,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],allocated to treatment,n/a,21,129,35,34,139,RO-may_prevent,820300-FS1,Eighty patients with DUODENAL ULCER were randomly allocated to treatment with tripotassium dicitrato bismuthate (TDB) tablets or CIMETIDINE,DUODENAL ULCER,CIMETIDINE
789214355,9/16/2015 09:37:08,1739443359,9/16/2015 09:36:52,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],for treatment of,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 09:51:31,1739446890,9/16/2015 09:50:30,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],Treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 09:53:36,1739447527,9/16/2015 09:53:19,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 09:59:29,1739449341,9/16/2015 09:59:07,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treatment,n/a,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:09:27,1739452634,9/16/2015 10:08:51,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:11:24,1739453184,9/16/2015 10:11:10,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],Treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:12:44,1739453503,9/16/2015 10:12:30,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],Treatment GOUT FLARE Oral COLCHICINE,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:15:33,1739454406,9/16/2015 10:15:21,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:18:19,1739455413,9/16/2015 10:18:01,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:19:13,1739455681,9/16/2015 10:18:38,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],GOUT FLARE COLCHICINE,prevent,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:25:39,1739457606,9/16/2015 10:24:17,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:35:05,1739460329,9/16/2015 10:34:48,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:40:14,1739461757,9/16/2015 10:39:26,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment of,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:40:49,1739461866,9/16/2015 10:40:24,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],Treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214355,9/16/2015 10:41:50,1739462235,9/16/2015 10:39:43,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,[TREATS],[TREATS],treatment,N/A,18,49,22,27,59,RO-may_prevent,820146-FS1,152  Treatment of GOUT FLARE  >     Oral  Use of COLCHICINE for treatment of gout flare is not recommended in patients with renal impairment who are receiving the drug for prevention of gout flares.,GOUT FLARE,COLCHICINE
789214356,9/16/2015 09:38:01,1739443632,9/16/2015 09:37:39,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],is underused in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 09:54:18,1739447725,9/16/2015 09:53:48,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],clinical trials;,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 09:55:05,1739447971,9/16/2015 09:54:49,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:11:04,1739453079,9/16/2015 10:10:35,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:13:02,1739453542,9/16/2015 10:12:21,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evidence safety,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:14:01,1739453826,9/16/2015 10:13:38,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],(ACETYLSALICYLIC ACID ASA underused INFARCTION clinical trials; its,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:16:39,1739454815,9/16/2015 10:16:12,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],underused,n/a,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:19:52,1739455876,9/16/2015 10:19:38,false,elite,1.0,30659754,USA,"","",162.250.145.204,[LOCATION],[LOCATION],in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:21:51,1739456470,9/16/2015 10:20:58,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],(ACETYLSALICYLIC ACID ASA MYOCARDIAL INFARCTION,cause,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:29:32,1739458700,9/16/2015 10:28:22,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:37:06,1739460844,9/16/2015 10:35:42,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],in,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:42:18,1739462339,9/16/2015 10:41:47,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:42:33,1739462381,9/16/2015 10:41:59,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,Drug,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:42:55,1739462480,9/16/2015 10:42:22,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],whether underused,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214356,9/16/2015 10:43:16,1739462539,9/16/2015 10:41:51,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,[PREVENTS],[PREVENTS],underused evidence efficacy authoritative recommendations about its use;,N/A,132,90,159,156,115,RO-may_prevent,820223-FS1,This article reviews the relevant published literature in order to assess whether aspirin (ACETYLSALICYLIC ACID ASA is underused in MYOCARDIAL INFARCTION (MI taking into account: (i) the evidence of efficacy and safety from clinical trials; (ii) authoritative recommendations about its use; and (iii) published drug utilisation studies.,MYOCARDIAL INFARCTION (MI,(ACETYLSALICYLIC ACID ASA
789214357,9/16/2015 10:54:52,1739466006,9/16/2015 10:54:27,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:02:47,1739468548,9/16/2015 11:02:07,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[ASSOCIATED_WITH] [CONTRAINDICATES],"[CONTRAINDICATES]
[ASSOCIATED_WITH]",past history OF,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:04:44,1739469142,9/16/2015 11:04:29,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:21:56,1739473611,9/16/2015 11:21:41,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [CONTRAINDICATES] [SIDE_EFFECT] [PART_OF] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]","oteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4)","oteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4)",90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:23:17,1739473883,9/16/2015 11:23:02,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],past history,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:24:18,1739474015,9/16/2015 11:23:58,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],with past history,n/a,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:27:34,1739474678,9/16/2015 11:27:15,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],THYROGLOBULIN,none,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:32:53,1739475915,9/16/2015 11:30:16,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],with past history,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:42:33,1739478374,9/16/2015 11:41:45,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[IS_A],[IS_A],marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES;,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:44:11,1739478816,9/16/2015 11:43:30,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],past history OF,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 11:52:48,1739480911,9/16/2015 11:52:22,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [SYMPTOM] [SIDE_EFFECT] [MANIFESTATION] [NONE],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 12:24:48,1739488391,9/16/2015 12:24:15,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 12:36:52,1739491681,9/16/2015 12:36:26,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],past history,n/a,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 12:43:32,1739493712,9/16/2015 12:42:56,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",OF with OF a,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214357,9/16/2015 12:44:19,1739493926,9/16/2015 12:42:50,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with history OF THYROID DISORDER GOITER AND THYROID NODULES;,N/A,90,30,117,135,71,RO-may_treat,820103-FS1,"Noteworthy were 1) the marked ELEVATION OF SERUM THYROGLOBULIN IN WOMEN with past history OF THYROID DISORDER GOITER AND THYROID NODULES; 2) the increase in goiter size in a third of the goitrous women, associated with biochemical evidence of functional stimulation of the gland; 3) the indirect evidence of partial thyroidal autonomy in goitrous patients; and 4) the increase in the number and size of thyroid nodules during gestation.",OF THYROID DISORDER GOITER AND THYROID NODULES,ELEVATION OF SERUM THYROGLOBULIN IN WOMEN
789214358,9/16/2015 12:56:03,1739497836,9/16/2015 12:55:31,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 13:09:19,1739502146,9/16/2015 13:08:45,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 13:16:32,1739504729,9/16/2015 13:16:07,false,elite,1.0,28548715,USA,"","",38.95.109.38,[MANIFESTATION],[MANIFESTATION],We compared all patients,n/a,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 13:19:52,1739505712,9/16/2015 13:19:28,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with without with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 13:42:25,1739514648,9/16/2015 13:41:58,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with without (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 13:54:14,1739518359,9/16/2015 13:53:37,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[ASSOCIATED_WITH] [IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with without with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:06:50,1739522524,9/16/2015 14:06:23,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:07:20,1739522691,9/16/2015 14:05:22,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with without with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:07:38,1739522866,9/16/2015 14:06:13,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",We compared all patients ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS examining separately patients,n/a,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:13:11,1739524892,9/16/2015 14:12:23,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],patients with,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:18:09,1739526571,9/16/2015 14:17:44,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [IS_A],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[IS_A]",with with with without with (a drug,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:31:53,1739531444,9/16/2015 14:30:29,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared all patients with ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS,n/a,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:40:23,1739534589,9/16/2015 14:39:41,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with ISONIAZID and MULTIDRUG RESISTANT TUBERCULOSIS,na,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:43:51,1739535976,9/16/2015 14:43:42,false,neodev,1.0,11291592,USA,MI,Taylor,99.170.106.105,[NONE],[NONE],none,n/a,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214358,9/16/2015 14:48:04,1739537584,9/16/2015 14:47:27,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,66,51,98,97,60,RO-may_prevent,820345-FS1,"We compared all patients in England and Wales with ISONIAZID  and MULTIDRUG RESISTANT TUBERCULOSIS in two time periods (1993 1994 and 1998 2000) with patients with fully sensitive tuberculosis, examining separately patients without and with previous tuberculosis (a proxy for primary and secondary drug resistant tuberculosis.",MULTIDRUG RESISTANT TUBERCULOSIS,ISONIAZID
789214359,9/16/2015 11:14:09,1739471547,9/16/2015 11:13:54,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],concentrations,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 11:27:12,1739474589,9/16/2015 11:26:52,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [CAUSES] [SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH] [SIDE_EFFECT] [PART_OF] [OTHER] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]
[OTHER]
[NONE]","d QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ] Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ] Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ] Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1","d QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ] Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ] Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ] Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1",483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 11:31:56,1739475697,9/16/2015 11:31:21,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[OTHER],[OTHER],use,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 11:36:46,1739476831,9/16/2015 11:36:25,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[PREVENTS],[PREVENTS],HYPOGLYCEMIA,none,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 11:54:51,1739481380,9/16/2015 11:53:58,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 11:58:39,1739482210,9/16/2015 11:57:50,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,There's no relation between the terms.,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 12:01:34,1739482940,9/16/2015 12:01:08,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [PREVENTS] [MANIFESTATION] [IS_A] [NONE],"[PREVENTS]
[SYMPTOM]
[MANIFESTATION]
[IS_A]
[NONE]",[TREATS],N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 12:35:53,1739491415,9/16/2015 12:35:19,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[CONTRAINDICATES],[CONTRAINDICATES],contraindicated,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 12:43:13,1739493546,9/16/2015 12:42:43,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],monitor,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 12:52:38,1739496658,9/16/2015 12:51:55,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 13:06:26,1739501254,9/16/2015 13:05:52,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 13:14:00,1739503816,9/16/2015 13:13:19,false,elite,1.0,28548715,USA,"","",38.95.109.38,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",reported Dosage adjustments not needed;,n/a,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 13:17:02,1739504889,9/16/2015 13:16:41,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 13:39:06,1739513670,9/16/2015 13:37:16,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF],[PART_OF],of,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214359,9/16/2015 13:53:18,1739517987,9/16/2015 13:52:49,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,483,550,495,494,578,RO-may_treat,820026-FS1,"prolonged QT interval, torsades de pointes) [ 1 ] Concomitant use contraindicated [ 1 ]   Digoxin Increased digoxin plasma concentrations [ 1 ] If used concomitantly, monitor digoxin plasma concentrations [ 1 ]   Ergot alkaloids (ergotamine, dihydroergotamine) Possible pharmacokinetic interaction (increased plasma concentrations of ergot alkaloids resulting in ergotism) [ 1 ] Concomitant use contraindicated [ 1 ]   Glipizide No clinically important pharmacokinetic interactions; HYPOGLYCEMIA reported [ 1 ] Dosage adjustments not needed; monitor BLOOD GLUCOSE CONCENTRATIONS according to current recommendations for patients with diabetes [ 1 ]   Halofantrine.",HYPOGLYCEMIA,BLOOD GLUCOSE CONCENTRATIONS
789214360,9/16/2015 09:33:07,1739442372,9/16/2015 09:32:40,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",changes in the epidemiology of,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 09:41:25,1739444512,9/16/2015 09:39:57,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],changes,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 09:48:05,1739446025,9/16/2015 09:46:15,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[PART_OF],[PART_OF],transmission of,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 09:50:08,1739446531,9/16/2015 09:49:54,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],inform,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 09:55:07,1739447979,9/16/2015 09:54:35,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],changes the epidemiology,n/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:02:11,1739450218,9/16/2015 10:01:21,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[IS_A],[IS_A],epidemiology,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:05:38,1739451404,9/16/2015 10:05:06,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],inform,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:07:19,1739451964,9/16/2015 10:06:48,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[MANIFESTATION],[MANIFESTATION],cases HEPATITIS B changes epidemiology of VIRAL HEPATITIS B INFECTION.,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:10:45,1739452977,9/16/2015 10:09:56,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[IS_A],[IS_A],HEPATITIS B VIRAL HEPATITIS B INFECTION.,N/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:11:26,1739453187,9/16/2015 10:09:43,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:11:48,1739453273,9/16/2015 10:11:23,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[IS_A],[IS_A],in,n/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:12:17,1739453381,9/16/2015 10:11:27,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],HEPATITIS B VIRAL HEPATITIS B INFECTION.,prevent,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:14:11,1739453911,9/16/2015 10:13:30,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],inform,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:32:07,1739459475,9/16/2015 10:31:51,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SYMPTOM],[SYMPTOM],inform,N/A,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214360,9/16/2015 10:37:21,1739460931,9/16/2015 10:35:59,false,elite,1.0,30782237,GBR,H9,London,164.143.240.34,[MANIFESTATION],[MANIFESTATION],changes,n/a,111,55,129,137,66,RO-may_prevent,820225-FS1,Changes in the pattern of transmission of new cases of HEPATITIS B inform us of changes in the epidemiology of VIRAL HEPATITIS B INFECTION.,VIRAL HEPATITIS B INFECTION,HEPATITIS B
789214361,9/16/2015 10:58:44,1739467202,9/16/2015 10:58:04,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:08:17,1739470039,9/16/2015 11:07:19,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],occurrence,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:23:58,1739473986,9/16/2015 11:23:44,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION] [ASSOCIATED_WITH] [SIDE_EFFECT] [PART_OF] [OTHER] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]
[OTHER]
[NONE]","ccurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing","ccurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing",77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:25:15,1739474239,9/16/2015 11:25:01,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],atypical MEASLES.,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:30:22,1739475368,9/16/2015 11:30:02,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MEASLES VIRUS,none,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:47:13,1739479567,9/16/2015 11:46:11,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[NONE],[NONE],N/A,The terms mean the same thing.,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:47:29,1739479663,9/16/2015 11:46:27,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[MANIFESTATION],[MANIFESTATION],occurrence antibodies MEASLES VIRUS,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:48:31,1739479891,9/16/2015 11:47:51,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],occurrence of,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 11:56:08,1739481679,9/16/2015 11:55:43,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[LOCATION] [CONTRAINDICATES] [SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]",[TREATS],N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 12:29:04,1739489363,9/16/2015 12:28:28,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[PART_OF],[PART_OF],was determined,n/a,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 12:39:30,1739492441,9/16/2015 12:39:07,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CAUSES],[CAUSES],antibodies,n/a,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 12:46:28,1739494643,9/16/2015 12:46:10,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 12:52:57,1739496769,9/16/2015 12:51:52,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",MEASLES VIRUS was determined from patients with atypical MEASLES.,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 13:02:10,1739499626,9/16/2015 13:01:51,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214361,9/16/2015 13:08:15,1739501867,9/16/2015 13:07:50,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],determined,n/a,77,77,131,83,90,RO-may_prevent,820347-FS1,"The occurrence of antibodies to the nucleoprotein and matrix (M) antigens of MEASLES VIRUS was determined in early and late measles convalescent sera and in sera from patients with multiple sclerosis, subacute sclerosing panencephalitis, chronic active hepatitis, and atypical MEASLES.",MEASLES,MEASLES VIRUS
789214362,9/16/2015 12:56:41,1739498020,9/16/2015 12:56:24,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 13:10:10,1739502529,9/16/2015 13:09:54,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 13:17:11,1739504904,9/16/2015 13:16:53,false,elite,1.0,28548715,USA,"","",38.95.109.38,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ranitidine were compared in the treatment,n/a,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 13:20:31,1739505917,9/16/2015 13:20:12,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 13:43:08,1739514904,9/16/2015 13:42:53,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 13:54:45,1739518527,9/16/2015 13:54:32,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:07:45,1739522906,9/16/2015 14:07:26,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],treatment,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:07:56,1739523026,9/16/2015 14:07:43,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:10:06,1739523868,9/16/2015 14:08:58,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",SUCRALFATE in treatment of DUODENAL ULCER in double blind study.,n/a,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:17:56,1739526501,9/16/2015 14:15:58,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:18:46,1739526747,9/16/2015 14:18:33,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",treatment of,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:34:42,1739532445,9/16/2015 14:33:35,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],compared in the treatment,n/a,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:41:09,1739534935,9/16/2015 14:40:49,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],SUCRALFATE in treatment of DUODENAL ULCER,na,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:48:55,1739538033,9/16/2015 14:48:29,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",treatment study.,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214362,9/16/2015 14:51:49,1739539110,9/16/2015 14:50:38,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[TREATS],[TREATS],SUCRALFATE and ranitidine,N/A,60,0,74,73,10,RO-may_prevent,820226-FS1,"SUCRALFATE and ranitidine were compared in the treatment of DUODENAL ULCER in this multicenter, randomized, double blind study.",DUODENAL ULCER,SUCRALFATE
789214363,9/16/2015 09:37:38,1739443483,9/16/2015 09:37:23,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],NITROGLYCERIN consumption,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 09:53:47,1739447581,9/16/2015 09:52:22,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],and,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 09:54:48,1739447886,9/16/2015 09:53:54,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:00:08,1739449545,9/16/2015 09:59:59,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],and,n/a,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:10:33,1739452941,9/16/2015 10:10:12,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],and,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:12:19,1739453392,9/16/2015 10:11:49,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],diaries.,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:13:37,1739453722,9/16/2015 10:13:07,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANGINA NITROGLYCERIN consumption weekly patient diaries.,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:16:11,1739454651,9/16/2015 10:15:51,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:19:35,1739455826,9/16/2015 10:19:00,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:20:57,1739456184,9/16/2015 10:20:34,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],ANGINA NITROGLYCERIN,prevent,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:28:20,1739458338,9/16/2015 10:27:12,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:35:40,1739460487,9/16/2015 10:35:24,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:41:46,1739462212,9/16/2015 10:40:57,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessed by,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:42:21,1739462347,9/16/2015 10:41:43,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[PART_OF],[PART_OF],and,N/A,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214363,9/16/2015 10:42:37,1739462385,9/16/2015 10:41:40,false,elite,1.0,30782237,GBR,H9,London,164.143.240.34,[TREATS],[TREATS],consumption,n/a,13,24,19,18,37,RO-may_prevent,820305-FS1,Frequency of ANGINA and NITROGLYCERIN consumption were assessed by weekly patient diaries.,ANGINA,NITROGLYCERIN
789214364,9/16/2015 09:33:46,1739442529,9/16/2015 09:33:08,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 09:42:38,1739444828,9/16/2015 09:41:26,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],Comparison,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 09:49:15,1739446310,9/16/2015 09:48:06,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,The sentence said there was little association between the two highlighted terms.,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 09:50:59,1739446751,9/16/2015 09:50:10,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"association,",N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 09:55:20,1739448042,9/16/2015 09:55:08,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with the degree,n/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:02:42,1739450365,9/16/2015 10:02:12,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],Comparison,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:06:10,1739451577,9/16/2015 10:05:40,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positivity,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:07:51,1739452109,9/16/2015 10:07:19,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Comparison ZEBRA ANTIBODY LEVELS with IMMUNODEFICIENCY,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:11:20,1739453165,9/16/2015 10:10:46,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[PART_OF],[PART_OF],Comparison of with the degree of,N/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:12:05,1739453351,9/16/2015 10:11:49,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"association,",n/a,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:12:33,1739453450,9/16/2015 10:11:27,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:13:07,1739453583,9/16/2015 10:12:19,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[LOCATION],[LOCATION],ZEBRA ANTIBODY LEVELS IMMUNODEFICIENCY HIV ZEBRA HIV,cause,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:14:38,1739454056,9/16/2015 10:14:14,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PART_OF],[PART_OF],with the degree of,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:32:25,1739459580,9/16/2015 10:32:09,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CONTRAINDICATES],[CONTRAINDICATES],with the degree,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214364,9/16/2015 10:36:54,1739460815,9/16/2015 10:36:16,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[PART_OF],[PART_OF],with the degree of,N/A,55,14,71,70,35,RO-may_treat,820107-FS1,"Comparison of ZEBRA ANTIBODY LEVELS with the degree of IMMUNODEFICIENCY (CD4 cell counts), CDC grouping, and HIV p24 antigen positivity showed little association, suggesting that induction of ZEBRA antibodies is an early event after HIV infection.",IMMUNODEFICIENCY,ZEBRA ANTIBODY LEVELS
789214365,9/16/2015 09:36:51,1739443290,9/16/2015 09:36:35,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],in the treatment of patients,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 09:50:29,1739446605,9/16/2015 09:50:08,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 09:53:11,1739447371,9/16/2015 09:52:54,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 09:59:05,1739449159,9/16/2015 09:58:53,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treatment,n/a,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:08:49,1739452464,9/16/2015 10:08:00,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:11:08,1739453122,9/16/2015 10:10:51,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:12:29,1739453425,9/16/2015 10:11:50,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],LOW MOLECULAR WEIGHT HEPARIN treatment PULMONARY EMBOLISM,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:15:19,1739454334,9/16/2015 10:15:03,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:17:58,1739455320,9/16/2015 10:17:44,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:18:36,1739455500,9/16/2015 10:17:59,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],LOW MOLECULAR WEIGHT HEPARIN PULMONARY EMBOLISM,the,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:24:15,1739457161,9/16/2015 10:22:13,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:34:46,1739460264,9/16/2015 10:34:29,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:39:25,1739461456,9/16/2015 10:39:04,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:39:42,1739461546,9/16/2015 10:39:10,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214365,9/16/2015 10:40:22,1739461774,9/16/2015 10:39:00,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treatment,N/A,74,0,92,91,28,RO-may_prevent,820306-FS1,LOW MOLECULAR WEIGHT HEPARIN vs heparin in the treatment of patients with PULMONARY EMBOLISM,PULMONARY EMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214366,9/16/2015 09:30:12,1739441685,9/16/2015 09:29:27,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",sensitive to INSULIN,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 09:31:06,1739441916,9/16/2015 09:29:41,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 09:39:16,1739443960,9/16/2015 09:37:49,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,The words appear in different parts of the sentence.,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 09:47:47,1739445966,9/16/2015 09:47:09,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],increased,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 09:52:22,1739447172,9/16/2015 09:52:04,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],and,n/a,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 09:53:54,1739447607,9/16/2015 09:53:04,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[CAUSES],[CAUSES],associated with,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 09:57:08,1739448535,9/16/2015 09:56:38,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:01:18,1739449927,9/16/2015 10:00:23,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:03:44,1739450697,9/16/2015 10:03:11,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],INSULIN DIABETES MELLITUS) increased risk Alzheimer's,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:05:41,1739451410,9/16/2015 10:04:09,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[NONE],[NONE],N/a,Whilst insulin is used to treat diabetes there is no indication in the sentence if this.,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:05:44,1739451430,9/16/2015 10:05:12,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],INSULIN TYPE 2 DIABETES MELLITUS),treat,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:08:42,1739452397,9/16/2015 10:08:06,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:11:17,1739453163,9/16/2015 10:10:36,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:28:49,1739458481,9/16/2015 10:27:01,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214366,9/16/2015 10:33:36,1739459888,9/16/2015 10:31:52,false,elite,1.0,30782237,GBR,H9,London,164.143.240.34,[CAUSES],[CAUSES],sensitive,n/a,180,77,130,203,84,RO-may_treat,820109-FS1,"Moreover, brain regions such as the hippocampus are sensitive to glucose and INSULIN and both type 1 and type 2 diabetes mellitus are associated with cognitive impairment and (for TYPE 2 DIABETES MELLITUS) increased risk for Alzheimer's disease.",TYPE 2 DIABETES MELLITUS,INSULIN
789214367,9/16/2015 10:54:25,1739465938,9/16/2015 10:54:04,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],THERAPY,Treat,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 10:55:47,1739466260,9/16/2015 10:55:18,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],responded to prolonged,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:02:05,1739468405,9/16/2015 11:01:29,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],responded to prolonged,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:04:28,1739469075,9/16/2015 11:01:54,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],papules,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:21:39,1739473580,9/16/2015 11:21:19,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [TREATS] [CONTRAINDICATES] [ASSOCIATED_WITH] [IS_A] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:23:00,1739473828,9/16/2015 11:22:44,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],eventually prolonged,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:23:58,1739473965,9/16/2015 11:23:36,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],responded,n/a,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:27:14,1739474598,9/16/2015 11:27:00,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],VARICELLA ZOSTER,none,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:30:14,1739475304,9/16/2015 11:28:47,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],eventually responded to,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:41:44,1739478156,9/16/2015 11:41:17,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:43:29,1739478640,9/16/2015 11:43:05,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],responded to,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 11:52:20,1739480755,9/16/2015 11:51:56,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [IS_A] [ASSOCIATED_WITH] [CONTRAINDICATES] [MANIFESTATION] [NONE],"[CAUSES]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[TREATS],N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 12:24:14,1739488256,9/16/2015 12:23:39,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[IS_A],[IS_A],responded to prolonged,n/a,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 12:36:26,1739491580,9/16/2015 12:36:06,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],prolonged HIGH DOSE,n/a,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214367,9/16/2015 12:42:52,1739493473,9/16/2015 12:42:25,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of a of,N/A,87,143,103,102,186,RO-may_prevent,820308-FS1,Findings of a biopsy specimen and viral culture of these papules subsequently revealed VARICELLA ZOSTER that eventually responded to prolonged HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT.,VARICELLA ZOSTER,HIGH DOSE ACYCLOVIR THERAPY AND DEBRIDEMENT
789214368,9/16/2015 11:13:52,1739471432,9/16/2015 11:13:36,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 11:26:50,1739474460,9/16/2015 11:26:36,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [SYMPTOM] [IS_A] [PART_OF] [CONTRAINDICATES] [MANIFESTATION] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[IS_A]
[PART_OF]
[NONE]",ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE  Is  CONGESTIVE HEART FAILURE ----related-to----   USED ONLY WHEN DIGITALIS AND DIURETICS CO,"ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE

Is  CONGESTIVE HEART FAILURE ----related-to----   USED ONLY WHEN DIGITALIS AND DIURETICS CO",95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 11:31:19,1739475569,9/16/2015 11:30:34,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 11:36:24,1739476748,9/16/2015 11:36:06,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[PREVENTS],[PREVENTS],CONGESTIVE HEART FAILURE,none,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 11:53:57,1739481156,9/16/2015 11:53:34,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 11:57:47,1739482047,9/16/2015 11:57:13,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],not adequately treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 12:01:06,1739482837,9/16/2015 12:00:41,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [MANIFESTATION] [SIDE_EFFECT] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 12:35:18,1739491245,9/16/2015 12:34:55,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treat,n/a,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 12:42:42,1739493415,9/16/2015 12:42:21,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],were USED,n/a,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 12:51:52,1739496403,9/16/2015 12:51:21,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 13:04:51,1739500657,9/16/2015 13:03:40,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[CONTRAINDICATES],[CONTRAINDICATES],USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 13:05:50,1739500991,9/16/2015 13:05:38,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 13:13:17,1739503604,9/16/2015 13:12:57,false,elite,1.0,28548715,USA,"","",38.95.109.38,[TREATS],[TREATS],treat,n/a,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 13:16:38,1739504753,9/16/2015 13:16:28,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214368,9/16/2015 13:37:14,1739512379,9/16/2015 13:36:49,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[TREATS],[TREATS],treat,N/A,95,29,119,118,73,RO-may_prevent,820309-FS1,"Initially, vasodilators were USED ONLY WHEN DIGITALIS AND DIURETICS COULD not adequately treat CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,USED ONLY WHEN DIGITALIS AND DIURETICS COULD
789214369,9/16/2015 10:58:02,1739466992,9/16/2015 10:57:19,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:07:18,1739469796,9/16/2015 11:07:04,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],in patients with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:23:42,1739473943,9/16/2015 11:23:26,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT] [PART_OF] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]","leland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE","leland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:25:00,1739474188,9/16/2015 11:24:41,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:30:01,1739475264,9/16/2015 11:29:47,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DIGOXIN,none,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:46:05,1739479255,9/16/2015 11:43:59,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],clearances in patients with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:46:25,1739479354,9/16/2015 11:45:44,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SIDE_EFFECT],[SIDE_EFFECT],The effects of captopril and DIGOXIN patients with CONGESTIVE HEART FAILURE,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:47:49,1739479751,9/16/2015 11:47:01,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],clearances in patients with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 11:55:41,1739481618,9/16/2015 11:55:13,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 12:28:27,1739489235,9/16/2015 12:27:48,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SIDE_EFFECT],[SIDE_EFFECT],effects with,n/a,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 12:39:06,1739492279,9/16/2015 12:38:44,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],effects of,n/a,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 12:46:07,1739494519,9/16/2015 12:45:47,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",A with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 12:51:49,1739496386,9/16/2015 12:50:53,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],The effects DIGOXIN clearances patients with CONGESTIVE HEART FAILURE,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 13:01:49,1739499501,9/16/2015 13:01:27,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[SIDE_EFFECT] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",effects of with,N/A,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214369,9/16/2015 13:10:12,1739502530,9/16/2015 13:09:36,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],The effects captopril,n/a,142,106,166,165,113,RO-may_prevent,820193-FS1,"Cleland JGF, Dargie HJ, Pettigrew A et al. The effects of captopril on serum digoxin and urinary urea and DIGOXIN clearances in patients with CONGESTIVE HEART FAILURE",CONGESTIVE HEART FAILURE,DIGOXIN
789214370,9/16/2015 10:51:17,1739465080,9/16/2015 10:50:36,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],resolution presence,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 10:52:17,1739465330,9/16/2015 10:51:36,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 10:57:25,1739466772,9/16/2015 10:56:50,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS] [OTHER],"[TREATS]
[OTHER]",treatment in the presence,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 10:59:16,1739467371,9/16/2015 10:58:55,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],presence,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:12:17,1739471057,9/16/2015 11:12:08,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],MALARIA,NONE,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:18:47,1739472851,9/16/2015 11:16:58,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],in the presence of,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:19:38,1739473056,9/16/2015 11:19:24,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [PREVENTS] [LOCATION] [CONTRAINDICATES] [SIDE_EFFECT] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the M,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the M,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:21:22,1739473491,9/16/2015 11:21:08,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],presence,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:22:04,1739473645,9/16/2015 11:21:47,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presence,n/a,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:22:50,1739473784,9/16/2015 11:21:22,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in presence of,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:25:24,1739474249,9/16/2015 11:25:10,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MALARIA,none,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:25:43,1739474294,9/16/2015 11:25:35,false,elite,1.0,33798502,USA,DE,"",108.59.8.208,[CONTRAINDICATES],[CONTRAINDICATES],RESISTANCE.,It makes sense,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:37:27,1739477031,9/16/2015 11:36:32,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[SYMPTOM],[SYMPTOM],presence of CHLOROQUINE RESISTANCE.,N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 11:49:36,1739480197,9/16/2015 11:49:11,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [SYMPTOM] [CONTRAINDICATES] [SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214370,9/16/2015 12:18:59,1739487177,9/16/2015 12:18:06,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[CAUSES],[CAUSES],pre treatment,n/a,108,157,115,114,179,RO-may_prevent,820150-FS1,"We conclude that pre hospital treatment ingested chloroquine contributes significantly to the resolution of MALARIA in children in Ghana, in the presence of CHLOROQUINE RESISTANCE.",MALARIA,CHLOROQUINE RESISTANCE
789214371,9/16/2015 09:37:22,1739443406,9/16/2015 09:37:09,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],TREATMENT,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 09:52:22,1739447169,9/16/2015 09:51:32,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],TREATMENT,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 09:53:53,1739447603,9/16/2015 09:53:37,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],TREATMENT,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 09:59:58,1739449503,9/16/2015 09:59:30,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],TREATMENT,n/a,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:10:11,1739452795,9/16/2015 10:09:29,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],TREATMENT,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:11:47,1739453260,9/16/2015 10:11:26,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:13:07,1739453572,9/16/2015 10:12:46,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:15:49,1739454530,9/16/2015 10:15:34,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],TREATMENT,n/a,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:18:58,1739455572,9/16/2015 10:18:21,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],TREATMENT for,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:20:33,1739456039,9/16/2015 10:19:14,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],CHLOROQUINE TREATMENT SYMPTOMATIC MALARIA INFECTION,treat,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:27:11,1739457954,9/16/2015 10:25:40,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:35:21,1739460374,9/16/2015 10:35:07,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],TREATMENT for,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:40:56,1739461895,9/16/2015 10:40:19,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],TREATMENT for,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:43:40,1739462651,9/16/2015 10:41:05,false,clixsense,1,26648627,GBR,"","",212.159.48.72,[TREATS],[TREATS],received,N/A,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214371,9/16/2015 10:44:23,1739462917,9/16/2015 10:44:00,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Trwat,55,29,74,83,50,RO-may_prevent,820273-FS1,"Group I received placebo and CHLOROQUINE TREATMENT for SYMPTOMATIC MALARIA INFECTION (i.e., no presumptive anti malarial treatment given.",SYMPTOMATIC MALARIA INFECTION,CHLOROQUINE TREATMENT
789214372,9/16/2015 10:52:11,1739465323,9/16/2015 10:51:18,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",VACCINE new VACCINE,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 10:52:39,1739465440,9/16/2015 10:52:19,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],VACCINE,Treat,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 10:58:37,1739467185,9/16/2015 10:57:32,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[OTHER],[OTHER],a new,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:00:29,1739467836,9/16/2015 10:59:17,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[IS_A],[IS_A],a new,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:19:51,1739473071,9/16/2015 11:18:49,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[IS_A],[IS_A],a new,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:19:59,1739473177,9/16/2015 11:19:39,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [CONTRAINDICATES] [SYMPTOM] [SIDE_EFFECT] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]","Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed)","Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed)",43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:21:38,1739473579,9/16/2015 11:21:23,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[IS_A],[IS_A],a new,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:22:29,1739473725,9/16/2015 11:22:05,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],"(adsorbed), a new",n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:25:45,1739474303,9/16/2015 11:25:25,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],RABIES VACCINE,none,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:38:16,1739477263,9/16/2015 11:37:30,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[IS_A],[IS_A],"RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:40:16,1739477726,9/16/2015 11:39:43,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]",a new,N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 11:50:02,1739480310,9/16/2015 11:49:39,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[LOCATION] [IS_A] [SYMPTOM] [DIAGNOSE_BY_TEST_OR_DRUG] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[IS_A]
[NONE]",[TREATS],N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 12:19:48,1739487324,9/16/2015 12:18:59,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[IS_A],[IS_A],"(adsorbed), a new",n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 12:34:56,1739491116,9/16/2015 12:34:14,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[IS_A],[IS_A],new,n/a,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214372,9/16/2015 12:41:04,1739492865,9/16/2015 12:39:41,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]","RHESUS DIPLOID RABIES VACCINE (adsorbed), new RABIES VACCINE",N/A,43,58,64,71,72,RO-may_prevent,820153-FS1,"Berlin BS, Mitchell JR, Burgoyne GH et al. RHESUS DIPLOID RABIES VACCINE (adsorbed), a new RABIES VACCINE",RHESUS DIPLOID RABIES VACCINE,RABIES VACCINE
789214373,9/16/2015 09:38:26,1739443763,9/16/2015 09:38:02,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Combined levothyroxine randomized controlled trial.,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 09:55:20,1739448041,9/16/2015 09:55:06,false,elite,1,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],compared with,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 09:55:30,1739448105,9/16/2015 09:54:19,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],trial.,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:12:50,1739453519,9/16/2015 10:11:05,false,neodev,1,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS] [OTHER],"[TREATS]
[OTHER]",in trial.,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:13:27,1739453679,9/16/2015 10:13:04,false,neodev,1,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],controlled,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:14:21,1739453997,9/16/2015 10:14:02,false,neodev,1,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],LEVOTHYROXINE HYPOTHYROIDISM: randomized controlled trial.,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:17:02,1739454984,9/16/2015 10:16:40,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],trial.,n/a,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:20:12,1739455934,9/16/2015 10:19:53,false,elite,1,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],liothyronine,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:22:20,1739456633,9/16/2015 10:21:53,false,neodev,1,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],LEVOTHYROXINE HYPOTHYROIDISM:,prevent,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:30:56,1739459096,9/16/2015 10:29:34,false,neodev,1,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:37:25,1739460934,9/16/2015 10:37:08,false,elite,1,30659677,USA,"","",162.252.172.126,[MANIFESTATION],[MANIFESTATION],compared with,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:43:02,1739462512,9/16/2015 10:42:34,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:43:10,1739462533,9/16/2015 10:42:23,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",controlled trial.,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:43:38,1739462615,9/16/2015 10:42:38,false,elite,1,30782237,GBR,H9,London,164.143.240.34,[TREATS],[TREATS],primary,n/a,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214373,9/16/2015 10:43:38,1739462627,9/16/2015 10:42:57,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[OTHER],[OTHER],compared with,N/A,132,101,146,145,114,RO-may_prevent,820154-FS1,"1]  Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with LEVOTHYROXINE alone in primary HYPOTHYROIDISM: a randomized controlled trial.",HYPOTHYROIDISM,LEVOTHYROXINE
789214374,9/16/2015 10:53:24,1739465643,9/16/2015 10:53:05,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 10:53:43,1739465763,9/16/2015 10:53:04,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],long term treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 10:59:51,1739467627,9/16/2015 10:59:29,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],long term treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:01:09,1739468093,9/16/2015 11:00:53,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:20:39,1739473326,9/16/2015 11:20:20,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [CAUSES] [SYMPTOM] [SIDE_EFFECT] [IS_A] [ASSOCIATED_WITH] [NONE],"[TREATS]
[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[NONE]",CONCLUSION In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,CONCLUSION In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:22:11,1739473683,9/16/2015 11:21:55,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],with SYMPTOMATIC,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:22:54,1739473819,9/16/2015 11:22:42,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],with,n/a,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:25:50,1739474316,9/16/2015 11:25:10,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment with,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:26:29,1739474435,9/16/2015 11:26:09,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],VENOUS THROMBOEMBOLISM,none,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:39:48,1739477597,9/16/2015 11:39:24,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:42:01,1739478226,9/16/2015 11:41:32,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment with,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 11:50:57,1739480472,9/16/2015 11:50:32,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[SYMPTOM]
[NONE]",[TREATS],N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 12:22:45,1739487973,9/16/2015 12:22:12,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment with,n/a,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 12:35:32,1739491307,9/16/2015 12:35:18,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214374,9/16/2015 12:41:45,1739493140,9/16/2015 12:41:06,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM treatment with LOW MOLECULAR WEIGHT HEPARIN,N/A,29,89,63,62,117,RO-may_prevent,820199-FS1,CONCLUSION  In patients with SYMPTOMATIC VENOUS THROMBOEMBOLISM long term treatment with LOW MOLECULAR WEIGHT HEPARIN is possibly as effective and safe as long term treatment with vitamin K antagonists.,SYMPTOMATIC VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
789214375,9/16/2015 13:19:32,1739505641,9/16/2015 13:19:12,false,elite,1.0,28548715,USA,"","",38.95.109.38,[ASSOCIATED_WITH],[ASSOCIATED_WITH],reference interval,n/a,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 13:23:18,1739506796,9/16/2015 13:22:42,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF],[PART_OF],of,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 13:46:30,1739516058,9/16/2015 13:46:14,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF],[PART_OF],of,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 13:57:53,1739519620,9/16/2015 13:57:36,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF],[PART_OF],of,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 14:10:30,1739524005,9/16/2015 14:10:12,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF],[PART_OF],of,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 14:10:36,1739524076,9/16/2015 14:10:13,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[SYMPTOM],[SYMPTOM],has,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 14:21:40,1739527867,9/16/2015 14:21:24,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF],[PART_OF],of,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 14:26:12,1739529402,9/16/2015 14:25:18,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CONTRAINDICATES],[CONTRAINDICATES],do not indicate,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 14:44:20,1739536189,9/16/2015 14:43:50,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CONTRAINDICATES],[CONTRAINDICATES],LOW COBALAMIN CONCENTRATIONS do not indicate patient has COBALAMIN DEFICIENCY,na,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 14:51:20,1739538958,9/16/2015 14:50:41,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[OTHER],[OTHER],do not indicate,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 15:00:20,1739542744,9/16/2015 14:59:16,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[MANIFESTATION],[MANIFESTATION],COBALAMIN COBALAMIN DEFICIENCY,N/A,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 15:03:34,1739544138,9/16/2015 15:02:29,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[SYMPTOM],[SYMPTOM],indicate that the patient has,N/a,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 15:03:42,1739544185,9/16/2015 15:02:38,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 15:04:57,1739544631,9/16/2015 15:02:41,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[OTHER],[OTHER],do not indicate do not exclude,They aren't related by any of the above options but it also says that one can't be excluded as a cause of the other,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214375,9/16/2015 15:10:54,1739546948,9/16/2015 15:09:18,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[OTHER],[OTHER],do not indicate that the patient in question has,n/a,78,0,98,97,28,RO-may_prevent,820353-FS1,LOW COBALAMIN CONCENTRATIONS do not indicate that the patient in question has COBALAMIN DEFICIENCY and values in the lower half of the reference interval do not exclude cobalamin deficiency.,COBALAMIN DEFICIENCY,LOW COBALAMIN CONCENTRATIONS
789214376,9/16/2015 10:49:02,1739464342,9/16/2015 10:48:05,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],approved treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 10:49:23,1739464438,9/16/2015 10:49:08,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatments,Treat,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 10:53:18,1739465609,9/16/2015 10:52:46,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 10:55:16,1739466088,9/16/2015 10:54:47,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 10:58:16,1739467083,9/16/2015 10:57:47,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:10:18,1739470444,9/16/2015 11:07:22,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],approved treatments of,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:11:43,1739470810,9/16/2015 11:11:28,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],OSTEOPOROSIS,NONE,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:18:46,1739472828,9/16/2015 11:18:09,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [SYMPTOM] [LOCATION] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",honates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,honates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:20:34,1739473324,9/16/2015 11:20:17,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:21:09,1739473444,9/16/2015 11:20:52,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[PREVENTS],[PREVENTS],treatments,n/a,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:24:00,1739473987,9/16/2015 11:23:21,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],RECEPTOR MODULATOR,none,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:25:09,1739474227,9/16/2015 11:24:44,false,elite,1,33798502,USA,DE,"",108.59.8.208,[TREATS],[TREATS],approved,It makes sense,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:35:10,1739476469,9/16/2015 11:34:49,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatments,N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:43:24,1739478615,9/16/2015 11:43:08,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],treatments,N/a,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214376,9/16/2015 11:48:09,1739479825,9/16/2015 11:47:43,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[CONTRAINDICATES]
[NONE]",[TREATS],N/A,114,51,142,140,86,RO-may_prevent,820354-FS1,Various bisphosphonates and the selective estrogen RECEPTOR MODULATOR (SERM RALOXIFENE are approved treatments of POSTMENOPAUSAL OSTEOPOROSIS,POSTMENOPAUSAL OSTEOPOROSIS,RECEPTOR MODULATOR (SERM RALOXIFENE
789214377,9/16/2015 09:30:33,1739441791,9/16/2015 09:30:13,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were positive for,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 09:32:43,1739442262,9/16/2015 09:31:07,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],serological results,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 09:39:56,1739444161,9/16/2015 09:39:17,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,The two parts are not related.,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 09:48:08,1739446038,9/16/2015 09:47:48,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],positive,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 09:52:34,1739447195,9/16/2015 09:52:23,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],were positive,n/a,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 09:54:46,1739447882,9/16/2015 09:53:55,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],and,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 09:59:33,1739449374,9/16/2015 09:57:09,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:01:41,1739450069,9/16/2015 10:01:21,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positive,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:04:21,1739450896,9/16/2015 10:03:44,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive hepatitis B SURFACE ANTIGEN positive for SERUM HEPATITIS B ANTIBODY,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:06:12,1739451576,9/16/2015 10:05:42,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[PART_OF],[PART_OF],serum hepatitis B SURFACE ANTIGEN (HBSAG,N/a,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:07:35,1739452031,9/16/2015 10:05:55,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],HEPATITIS ANTIBODY,treat,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:09:12,1739452549,9/16/2015 10:08:43,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],and,n/a,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:11:36,1739453224,9/16/2015 10:11:19,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],positive,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:29:27,1739458689,9/16/2015 10:28:52,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],positive,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214377,9/16/2015 10:34:27,1739460199,9/16/2015 10:32:29,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],results of,N/A,139,90,155,164,112,RO-may_prevent,820277-FS1,The serological results of 82 Whites showed that 1.2% were positive for serum hepatitis B SURFACE ANTIGEN (HBSAG and 21% were positive for SERUM HEPATITIS B ANTIBODY (HBAb.,SERUM HEPATITIS B ANTIBODY,SURFACE ANTIGEN (HBSAG
789214378,9/16/2015 09:40:45,1739444327,9/16/2015 09:38:58,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],which acts directly on cells),N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 09:56:09,1739448221,9/16/2015 09:55:52,false,elite,1.0,30659615,USA,"","",162.250.145.234,[OTHER],[OTHER],Hypofunction:,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 09:57:48,1739448726,9/16/2015 09:56:23,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],acts,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:15:14,1739454283,9/16/2015 10:14:36,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],increases,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:15:41,1739454464,9/16/2015 10:14:51,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],(except,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:15:53,1739454566,9/16/2015 10:15:15,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],GROWTH HORMONE acts directly on cells) DWARFISM,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:18:16,1739455410,9/16/2015 10:17:52,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],which acts,n/a,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:21:45,1739456447,9/16/2015 10:21:28,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SIDE_EFFECT],[SIDE_EFFECT],effects,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:24:28,1739457221,9/16/2015 10:23:34,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],GROWTH HORMONE DWARFISM,cause,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:35:08,1739460331,9/16/2015 10:33:56,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:39:04,1739461365,9/16/2015 10:38:11,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PART_OF],[PART_OF],Hypofunction:,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:44:57,1739463052,9/16/2015 10:44:24,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[CAUSES],[CAUSES],increases Diabetes,Causes,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:45:04,1739463103,9/16/2015 10:44:10,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],effects,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:45:38,1739463245,9/16/2015 10:44:32,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[ASSOCIATED_WITH],[ASSOCIATED_WITH],acts directly,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214378,9/16/2015 10:50:57,1739464958,9/16/2015 10:49:36,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],decrease,N/A,284,224,293,291,238,RO-may_treat,820036-FS1,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
789214379,9/16/2015 13:12:13,1739503215,9/16/2015 13:11:46,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 13:18:42,1739505365,9/16/2015 13:18:27,false,elite,1.0,28548715,USA,"","",38.95.109.38,[LOCATION],[LOCATION],"area of secondary hyperalgesia,",n/a,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 13:22:19,1739506466,9/16/2015 13:22:01,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 13:45:45,1739515793,9/16/2015 13:45:04,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 13:57:11,1739519367,9/16/2015 13:56:21,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:09:45,1739523776,9/16/2015 14:09:26,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[PART_OF],[PART_OF],CAPSAICIN INDUCED PAIN INTENSITY,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:09:48,1739523785,9/16/2015 14:09:28,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:20:57,1739527593,9/16/2015 14:20:40,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",of of with,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:24:50,1739528977,9/16/2015 14:24:17,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[SYMPTOM],[SYMPTOM],"pain area,",N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:43:28,1739535866,9/16/2015 14:42:58,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CAPSAICIN INDUCED PAIN INTENSITY together with pressure PAIN thresholds.,na,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:50:21,1739538557,9/16/2015 14:50:07,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SYMPTOM],[SYMPTOM],were recorded,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 14:57:51,1739541579,9/16/2015 14:56:59,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[CAUSES],[CAUSES],CAPSAICIN INDUCED PAIN INTENSITY pain,N/A,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 15:00:10,1739542652,9/16/2015 14:58:18,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,The sentence only says that data were recorded within these pain threshold areas.,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 15:00:16,1739542715,9/16/2015 14:59:02,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214379,9/16/2015 15:01:46,1739543354,9/16/2015 15:01:22,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[PART_OF],[PART_OF],CAPSAICIN INDUCED PAIN INTENSITY,N/a,22,4,42,25,36,RO-may_prevent,820278-FS1,"The CAPSAICIN INDUCED PAIN INTENSITY pain area, the area of secondary hyperalgesia, the area of visible flare and vasomotor reactions were recorded together with cutaneous heat, electrical and pressure PAIN thresholds.",PAIN,CAPSAICIN INDUCED PAIN INTENSITY
789214380,9/16/2015 09:32:38,1739442217,9/16/2015 09:32:06,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Dose dependent reductions in,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 09:39:56,1739444159,9/16/2015 09:39:00,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],INFUSIONS.,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 09:46:11,1739445601,9/16/2015 09:45:01,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[OTHER],[OTHER],reductions in,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 09:49:53,1739446477,9/16/2015 09:49:37,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 09:54:35,1739447838,9/16/2015 09:54:18,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],and the,n/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:01:20,1739449936,9/16/2015 10:00:40,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were noted in,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:05:04,1739451217,9/16/2015 10:04:33,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],noted,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:06:48,1739451816,9/16/2015 10:06:17,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],reductions in STROKING PAIN SCORES KETAMINE INFUSIONS.,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:09:41,1739452687,9/16/2015 10:07:46,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:09:55,1739452736,9/16/2015 10:09:22,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],reductions in,N/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:11:22,1739453174,9/16/2015 10:11:04,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[LOCATION],[LOCATION],in,n/a,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:11:25,1739453186,9/16/2015 10:10:59,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],STROKING PAIN SCORES KETAMINE,you,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:13:27,1739453683,9/16/2015 10:13:10,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],increases,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:31:48,1739459392,9/16/2015 10:31:15,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],increases,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214380,9/16/2015 10:36:50,1739460766,9/16/2015 10:35:28,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were noted,N/A,77,140,90,96,158,RO-may_prevent,820311-FS1,"Dose dependent increases in cold and cold pain thresholds, and reductions in STROKING PAIN SCORES were noted in both the alfentanil and the KETAMINE INFUSIONS.",STROKING PAIN SCORES,KETAMINE INFUSIONS
789214381,9/16/2015 10:50:36,1739464802,9/16/2015 10:49:40,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",correlation between,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 10:51:35,1739465161,9/16/2015 10:51:11,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 10:56:50,1739466596,9/16/2015 10:54:44,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[ASSOCIATED_WITH],[ASSOCIATED_WITH],changes and clinical significance,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 10:58:54,1739467286,9/16/2015 10:58:36,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:12:07,1739470955,9/16/2015 11:11:57,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],cirrhosis,NONE,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:16:55,1739472346,9/16/2015 11:15:03,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],dysbolism of and,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:19:22,1739472992,9/16/2015 11:19:05,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [LOCATION] [CAUSES] [MANIFESTATION] [ASSOCIATED_WITH] [NONE],"[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[NONE]",The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the M,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the M,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:21:06,1739473439,9/16/2015 11:20:51,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:21:20,1739473486,9/16/2015 11:20:06,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],dysbolism of,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:21:46,1739473588,9/16/2015 11:21:23,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],and,n/a,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:25:09,1739474222,9/16/2015 11:24:39,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],FOLIC ACID,none,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:25:33,1739474270,9/16/2015 11:25:23,false,elite,1.0,33798502,USA,DE,"",108.59.8.208,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],liver,It makes sense,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:36:29,1739476756,9/16/2015 11:35:40,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes,N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 11:49:09,1739480109,9/16/2015 11:48:40,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES] [OTHER] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[CONTRAINDICATES]
[OTHER]
[NONE]",[TREATS],N/A,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214381,9/16/2015 12:18:04,1739486985,9/16/2015 12:16:58,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[MANIFESTATION],[MANIFESTATION],changes were discussed.,n/a,92,57,105,104,67,RO-may_treat,820113-FS1,The correlation between liver cirrhosis and dysbolism of FOLIC ACID and vitamin B12 and the MEGALOBLASTIC changes and clinical significance were discussed.,MEGALOBLASTIC,FOLIC ACID
789214382,9/16/2015 10:56:08,1739466366,9/16/2015 10:55:40,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:05:49,1739469423,9/16/2015 11:05:26,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[LOCATION],[LOCATION],in,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:22:31,1739473739,9/16/2015 11:22:14,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [TREATS] [CAUSES] [SYMPTOM] [ASSOCIATED_WITH] [MANIFESTATION] [CONTRAINDICATES] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",xcretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,xcretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:23:49,1739473953,9/16/2015 11:23:34,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SYMPTOM],[SYMPTOM],existence three metabolic,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:24:43,1739474135,9/16/2015 11:24:30,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[OTHER],[OTHER],metabolic pathways,n/a,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:28:50,1739474987,9/16/2015 11:28:36,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ASTHMA,none,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:40:19,1739477765,9/16/2015 11:37:31,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],patients and in rats three metabolic pathways of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:43:44,1739478696,9/16/2015 11:42:52,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],existence of three metabolic pathways of THEOPHYLLINE.,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:45:43,1739479162,9/16/2015 11:44:36,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],ingestion,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 11:53:53,1739481129,9/16/2015 11:53:18,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[PREVENTS] [SIDE_EFFECT] [LOCATION] [IS_A] [NONE],"[PREVENTS]
[LOCATION]
[SIDE_EFFECT]
[IS_A]
[NONE]",[TREATS],N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 12:26:02,1739488641,9/16/2015 12:25:14,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],suggest of,n/a,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 12:37:48,1739491933,9/16/2015 12:37:32,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],ingestion,n/a,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 12:44:29,1739493964,9/16/2015 12:44:05,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF],[PART_OF],of,v,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 12:48:01,1739495234,9/16/2015 12:46:36,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",ASTHMA patients existence of three metabolic pathways of THEOPHYLLINE.,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214382,9/16/2015 13:00:17,1739498984,9/16/2015 12:59:49,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[PART_OF],[PART_OF],of of of,N/A,103,184,109,108,196,RO-may_treat,820114-FS1,Excretory patterns after theophylline ingestion before and during the administration of allopurinol in ASTHMA patients and in rats suggest the existence of three metabolic pathways of THEOPHYLLINE.,ASTHMA,THEOPHYLLINE
789214383,9/16/2015 09:38:57,1739443869,9/16/2015 09:38:44,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 09:55:50,1739448173,9/16/2015 09:55:36,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 09:56:22,1739448294,9/16/2015 09:56:03,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:14:35,1739454051,9/16/2015 10:14:01,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:14:50,1739454151,9/16/2015 10:13:44,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:15:14,1739454278,9/16/2015 10:14:58,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],ASTHMA receiving ZAFIRLUKAST,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:17:50,1739455271,9/16/2015 10:17:29,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],receiving,n/a,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:21:26,1739456328,9/16/2015 10:20:38,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],cardiomyopathy following,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:23:32,1739456958,9/16/2015 10:23:08,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],ASTHMA ZAFIRLUKAST,prevent,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:33:55,1739459996,9/16/2015 10:32:12,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:38:08,1739461094,9/16/2015 10:37:46,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:43:59,1739462751,9/16/2015 10:43:35,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:44:09,1739462835,9/16/2015 10:43:39,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[SIDE_EFFECT],[SIDE_EFFECT],withdrawal,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:46:15,1739463457,9/16/2015 10:44:06,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214383,9/16/2015 10:48:11,1739464096,9/16/2015 10:47:50,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],receiving,N/A,151,168,157,156,179,RO-may_prevent,820236-FS1,"Wechsler ME, Garpestad E, Flier SR et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with ASTHMA receiving ZAFIRLUKAST",ASTHMA,ZAFIRLUKAST
789214384,9/16/2015 13:20:18,1739505848,9/16/2015 13:19:48,false,elite,1.0,28548715,USA,"","",38.95.109.38,[PART_OF],[PART_OF],using a combination of,n/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 13:24:23,1739507106,9/16/2015 13:23:58,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[SIDE_EFFECT] [IS_A] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",effect of with a a of,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 13:47:26,1739516301,9/16/2015 13:46:56,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF] [SIDE_EFFECT] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",effect of with a of,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 13:59:11,1739520018,9/16/2015 13:58:25,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[SIDE_EFFECT] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]",effect with a a,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 14:11:26,1739524300,9/16/2015 14:10:52,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[PART_OF],[PART_OF],concentrations found,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 14:12:11,1739524594,9/16/2015 14:10:59,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[SIDE_EFFECT] [PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",effect with a a of of,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 14:22:40,1739528205,9/16/2015 14:22:13,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[SIDE_EFFECT] [PART_OF] [IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[IS_A]
[PART_OF]",effect of with a of,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 14:27:22,1739529813,9/16/2015 14:26:31,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[MANIFESTATION],[MANIFESTATION],found during,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 14:45:50,1739536771,9/16/2015 14:45:20,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[SYMPTOM],[SYMPTOM],GLUCAGON concentrations found during HYPOGLYCEMIA,na,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 14:51:49,1739539092,9/16/2015 14:51:33,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SYMPTOM],[SYMPTOM],found,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 15:06:09,1739544967,9/16/2015 15:05:06,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 15:06:39,1739545158,9/16/2015 15:05:03,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[PART_OF],[PART_OF],found during,N/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 15:07:41,1739545575,9/16/2015 15:05:53,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,It doesn't specify if they are related. It just says that levels were tested.,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 15:14:00,1739548235,9/16/2015 15:12:36,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[MANIFESTATION],[MANIFESTATION],concentrations found during,n/a,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214384,9/16/2015 15:15:35,1739548936,9/16/2015 15:14:21,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[CAUSES],[CAUSES],found during HYPOGLYCEMIA,N/A,226,189,238,237,197,RO-may_treat,820115-FS1,"To assess the effect of glucagon on renal and hepatic glutamine gluconeogenesis, we infused six normal healthy postabsorptive subjects with glucagon at a rate chosen to produce circulating GLUCAGON concentrations found during HYPOGLYCEMIA and, using a combination of isotopic and net balance techniques, determined the systemic, renal, and hepatic glucose release and renal and hepatic production of glucose from glutamine.",HYPOGLYCEMIA,GLUCAGON
789214385,9/16/2015 10:55:38,1739466227,9/16/2015 10:54:54,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[NONE],[NONE],none,None,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:05:25,1739469325,9/16/2015 11:04:46,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:22:12,1739473686,9/16/2015 11:21:58,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [TREATS] [LOCATION] [MANIFESTATION] [CONTRAINDICATES] [SIDE_EFFECT] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[OTHER]
[NONE]","he pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on","he pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on",118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:23:33,1739473928,9/16/2015 11:23:19,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:24:30,1739474076,9/16/2015 11:24:19,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[TREATS],[TREATS],treatment,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:28:35,1739474912,9/16/2015 11:27:35,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],PENTAMIDINE AEROSOL,none,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:34:10,1739476220,9/16/2015 11:32:56,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:42:50,1739478445,9/16/2015 11:42:35,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:44:35,1739478929,9/16/2015 11:44:12,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 11:53:16,1739481003,9/16/2015 11:52:51,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 12:25:12,1739488511,9/16/2015 12:24:49,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treatment of,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 12:37:31,1739491855,9/16/2015 12:36:52,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment,n/a,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 12:44:00,1739493860,9/16/2015 12:43:35,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [TREATS],"[TREATS]
[PART_OF]",of treatment of,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 12:46:35,1739494710,9/16/2015 12:44:20,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],PENTAMIDINE AEROSOL in treatment of PNEUMOCYSTIS CARINII PNEUMONIA,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214385,9/16/2015 12:52:54,1739496744,9/16/2015 12:49:58,false,fusioncash,1.0,21457135,USA,FL,Orlando,71.42.61.239,[TREATS],[TREATS],treatment,N/A,118,78,148,147,97,RO-may_prevent,820358-FS1,"From the pharmacological point of view, these studies prove the advantages of PENTAMIDINE AEROSOL in the treatment of PNEUMOCYSTIS CARINII PNEUMONIA (PCP) and provide information on extrarenal excretion mechanisms and deep compartments.",PNEUMOCYSTIS CARINII PNEUMONIA,PENTAMIDINE AEROSOL
789214386,9/16/2015 10:54:01,1739465857,9/16/2015 10:53:45,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treated,Treat,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 10:55:17,1739466089,9/16/2015 10:54:37,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[MANIFESTATION],[MANIFESTATION],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:01:22,1739468174,9/16/2015 11:00:25,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],newborns treated with,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:01:53,1739468351,9/16/2015 11:01:26,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:21:17,1739473456,9/16/2015 11:21:00,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[MANIFESTATION] [PREVENTS] [TREATS] [CAUSES] [LOCATION] [SIDE_EFFECT] [IS_A] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[SIDE_EFFECT]
[IS_A]
[NONE]",The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:22:42,1739473763,9/16/2015 11:22:29,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:23:34,1739473929,9/16/2015 11:23:16,false,bitcoinget,1.0,31256687,USA,NY,Brooklyn,24.146.181.193,[CAUSES],[CAUSES],developed,n/a,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:27:00,1739474514,9/16/2015 11:26:44,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ACYCLOVIR,none,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:28:44,1739474967,9/16/2015 11:27:31,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[SIDE_EFFECT],[SIDE_EFFECT],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:41:15,1739478048,9/16/2015 11:40:44,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:43:03,1739478504,9/16/2015 11:42:25,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],developed,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 11:51:53,1739480678,9/16/2015 11:51:29,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[SYMPTOM] [CAUSES] [PREVENTS] [IS_A] [NONE],"[PREVENTS]
[CAUSES]
[SYMPTOM]
[IS_A]
[NONE]",[TREATS],N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 12:23:38,1739488139,9/16/2015 12:23:17,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[TREATS],[TREATS],treated with,n/a,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 12:36:06,1739491490,9/16/2015 12:35:49,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CONTRAINDICATES],[CONTRAINDICATES],treated with developed,n/a,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214386,9/16/2015 12:42:49,1739493438,9/16/2015 12:41:47,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA,N/A,80,60,98,107,69,RO-may_prevent,820359-FS1,The newborns treated with varicella hyperimmunoglobulin and ACYCLOVIR developed ABORTIVE VARICELLA EXANTHEMA without further complications.,ABORTIVE VARICELLA EXANTHEMA,ACYCLOVIR
789214387,9/16/2015 13:19:47,1739505695,9/16/2015 13:19:34,false,elite,1.0,28548715,USA,"","",38.95.109.38,[TREATS],[TREATS],effective in reducing pain,n/a,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 13:23:56,1739506969,9/16/2015 13:23:21,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",effective effective with or,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 13:46:54,1739516147,9/16/2015 13:46:33,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH] [PART_OF],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",effective effective with or of,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 13:58:22,1739519799,9/16/2015 13:57:56,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[SIDE_EFFECT] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",effective effective with of,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 14:10:51,1739524166,9/16/2015 14:10:36,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],reducing,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 14:10:56,1739524174,9/16/2015 14:10:32,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[SIDE_EFFECT] [ASSOCIATED_WITH] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",effective effective with or of,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 14:22:10,1739527975,9/16/2015 14:21:41,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[SIDE_EFFECT] [PART_OF] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",effective effective with or of,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 14:26:30,1739529511,9/16/2015 14:26:12,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",effective in reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 14:45:17,1739536540,9/16/2015 14:44:24,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],NAPROXEN effective in reducing PAIN,na,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 14:51:33,1739539024,9/16/2015 14:51:21,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[PREVENTS],[PREVENTS],reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 15:04:57,1739544629,9/16/2015 15:04:23,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],appears to be effective in reducing pain,N/a,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 15:04:59,1739544640,9/16/2015 15:03:45,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 15:05:53,1739544902,9/16/2015 15:05:03,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[TREATS],[TREATS],effective in reducing pain and swelling,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 15:09:14,1739546232,9/16/2015 15:07:27,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],effective in reducing,n/a,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214387,9/16/2015 15:14:20,1739548443,9/16/2015 15:13:17,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[TREATS],[TREATS],effective reducing pain,N/A,124,0,49,127,8,RO-may_prevent,820315-FS1,NAPROXEN appears to be effective in reducing pain and swelling in acute gout and is an effective analgesic in patients with PAIN following surgery or trauma and in pain of dysmenorrhoea.,PAIN,NAPROXEN
789214388,9/16/2015 11:12:45,1739471170,9/16/2015 11:12:30,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SYMPTOM],[SYMPTOM],adverse,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:25:43,1739474284,9/16/2015 11:25:26,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[PREVENTS] [TREATS] [CAUSES] [IS_A] [SYMPTOM] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoi,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoi,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:28:21,1739474843,9/16/2015 11:27:59,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],on,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:31:59,1739475699,9/16/2015 11:31:46,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],TIROFIBAN,none,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:51:14,1739480553,9/16/2015 11:50:43,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:52:00,1739480694,9/16/2015 11:51:23,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],Effects of on,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:54:04,1739481187,9/16/2015 11:52:39,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Effects of on adverse cardiac events,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 11:59:07,1739482334,9/16/2015 11:58:44,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[PART_OF] [CAUSES] [SIDE_EFFECT] [MANIFESTATION] [NONE],"[CAUSES]
[MANIFESTATION]
[SIDE_EFFECT]
[PART_OF]
[NONE]",[TREATS],N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 12:32:19,1739490283,9/16/2015 12:31:40,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SIDE_EFFECT],[SIDE_EFFECT],Effects of,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 12:41:32,1739493045,9/16/2015 12:41:09,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],on adverse cardiac events,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 12:48:46,1739495400,9/16/2015 12:48:23,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[PART_OF] [SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",Effects of with OR,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 12:58:32,1739498476,9/16/2015 12:57:09,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 13:04:21,1739500371,9/16/2015 13:04:04,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[SIDE_EFFECT] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]
[PART_OF]",Effects of WITH,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 13:11:50,1739503034,9/16/2015 13:11:29,false,elite,1.0,28548715,USA,"","",38.95.109.38,[CAUSES],[CAUSES],Effects of platelet glycoprotein,n/a,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214388,9/16/2015 13:14:38,1739503971,9/16/2015 13:13:08,false,fusioncash,1.0,21457135,USA,FL,Orlando,71.42.61.239,[TREATS],[TREATS],Effects platelet glycoprotein IIb/IIIa blockade TIROFIBAN,N/A,92,56,124,143,65,RO-may_treat,820081-FS1,Effects of platelet glycoprotein IIb/IIIa blockade with TIROFIBAN on adverse cardiac events IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL infarction undergoing coronary angioplasty.,IN PATIENTS WITH UNSTABLE ANGINA OR ACUTE MYOCARDIAL,TIROFIBAN
789214389,9/16/2015 13:19:11,1739505539,9/16/2015 13:18:44,false,elite,1.0,28548715,USA,"","",38.95.109.38,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Binding studies,n/a,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 13:22:39,1739506589,9/16/2015 13:22:22,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",drugs: with,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 13:46:10,1739515917,9/16/2015 13:45:49,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",drugs: with,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 13:57:31,1739519470,9/16/2015 13:57:14,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",drugs: with,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:10:09,1739523895,9/16/2015 14:09:50,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",drugs: with,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:10:12,1739523907,9/16/2015 14:09:46,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],bind mainly,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:21:22,1739527777,9/16/2015 14:20:59,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",drugs: with,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:25:18,1739529135,9/16/2015 14:24:50,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],drugs:,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:43:47,1739535964,9/16/2015 14:43:28,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS drugs: ISONIAZID;,na,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:50:40,1739538661,9/16/2015 14:50:22,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],tested.,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 14:59:13,1739542169,9/16/2015 14:57:55,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[PREVENTS],[PREVENTS],TUBERCULOSIS ISONIAZID;,N/A,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 15:02:28,1739543642,9/16/2015 15:01:47,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],to the TUBERCULOSIS drugs: ISONIAZID;,N/a,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 15:02:36,1739543683,9/16/2015 15:00:17,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 15:02:40,1739543714,9/16/2015 15:00:12,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,"They are only related in the sense that Isoniazid is a drug for Tuberculosis but it doesn't talk about it being used to treat it, just that it was used in the study.",73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214389,9/16/2015 15:07:20,1739545464,9/16/2015 15:05:54,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],bind mainly to the TUBERCULOSIS drugs: ISONIAZID;,n/a,73,105,85,84,114,RO-may_prevent,820160-FS1,Binding studies reveal that alpha 1 acid glycoprotein bind mainly to the TUBERCULOSIS drugs: rifampicin; ISONIAZID; pyrazinamide; p aminosalicylic acid; capreomycin; ethionamide; levofloxacin and ofloxacin out with the therapeutic plasma range tested.,TUBERCULOSIS,ISONIAZID
789214390,9/16/2015 09:31:41,1739442009,9/16/2015 09:31:26,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],triple therapy with,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 09:37:58,1739443611,9/16/2015 09:37:07,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 09:43:57,1739445099,9/16/2015 09:43:13,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,There is no positive relationship between these words.,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 09:49:19,1739446338,9/16/2015 09:49:04,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],with,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 09:53:55,1739447625,9/16/2015 09:53:43,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],and,n/a,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 09:59:02,1739449123,9/16/2015 09:58:27,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:03:40,1739450671,9/16/2015 10:03:14,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:05:51,1739451453,9/16/2015 10:05:25,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],"bleeding WARFARIN aspirin, patients ATRIAL FIBRILLATION",N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:05:56,1739451482,9/16/2015 10:05:06,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:08:49,1739452433,9/16/2015 10:07:27,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[SIDE_EFFECT],[SIDE_EFFECT],Risk of bleeding in patients,N/a,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:10:18,1739452832,9/16/2015 10:09:36,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[CAUSES],[CAUSES],WARFARIN ATRIAL FIBRILLATION,is,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:10:36,1739452953,9/16/2015 10:10:18,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],therapy,n/a,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:12:51,1739453520,9/16/2015 10:12:34,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:30:54,1739459091,9/16/2015 10:30:34,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214390,9/16/2015 10:35:27,1739460400,9/16/2015 10:34:28,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],therapy,N/A,122,71,142,140,79,RO-may_treat,820041-FS1,"2010 09 13  Risk of bleeding with single, dual, or triple therapy with WARFARIN aspirin, and clopidogrel in patients with ATRIAL FIBRILLATION",ATRIAL FIBRILLATION,WARFARIN
789214391,9/16/2015 13:24:44,1739507213,9/16/2015 13:24:27,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 13:47:47,1739516388,9/16/2015 13:47:29,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 13:59:36,1739520142,9/16/2015 13:59:14,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 14:12:03,1739524533,9/16/2015 14:11:27,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],with aspirin,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 14:12:41,1739524726,9/16/2015 14:12:16,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 14:23:06,1739528368,9/16/2015 14:22:42,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",or with,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 14:27:43,1739529977,9/16/2015 14:27:23,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],after acute myocardial infarction,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 14:46:26,1739536967,9/16/2015 14:45:51,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],after acute myocardial infarction ASPIRIN MYOCARDIAL INFARCTION,na,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 14:52:29,1739539323,9/16/2015 14:51:50,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",was superior increased bleeding,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 15:07:19,1739545480,9/16/2015 15:06:12,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 15:07:37,1739545538,9/16/2015 15:06:40,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],was superior to aspirin alone after acute myocardial infarction,N/a,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 15:09:02,1739546130,9/16/2015 15:07:42,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[NONE],[NONE],N/A,The sentence itself does not indicate a relationship.,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 15:11:47,1739547324,9/16/2015 15:10:58,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],Warfarin,n/a,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 15:16:49,1739549436,9/16/2015 15:15:37,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[TREATS],[TREATS],aspirin superior,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214391,9/16/2015 15:17:36,1739549792,9/16/2015 15:15:30,false,neodev,1.0,32499893,USA,CA,San Jose,23.27.248.207,[TREATS],[TREATS],ASPIRIN MYOCARDIAL INFARCTION,N/A,161,144,182,181,151,RO-may_prevent,820361-FS1,Warfarin alone or with aspirin was superior to aspirin alone after acute myocardial infarction but increased bleeding  Keywords: Anticoagulants ASPIRIN Warfarin MYOCARDIAL INFARCTION  ACP Journal Club.,MYOCARDIAL INFARCTION,ASPIRIN
789214392,9/16/2015 09:30:48,1739441866,9/16/2015 09:30:34,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 09:34:54,1739442819,9/16/2015 09:32:44,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 09:40:45,1739444325,9/16/2015 09:39:57,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 09:48:31,1739446162,9/16/2015 09:48:09,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 09:52:46,1739447312,9/16/2015 09:52:34,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],relieve PAIN,n/a,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 09:56:07,1739448212,9/16/2015 09:54:47,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:01:08,1739449863,9/16/2015 09:59:35,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[TREATS] [NONE],"[TREATS]
[NONE]",good,good,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:02:05,1739450205,9/16/2015 10:01:43,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[PREVENTS],[PREVENTS],relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:04:38,1739451014,9/16/2015 10:04:22,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],CAPSAICIN relieve PAIN,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:06:28,1739451690,9/16/2015 10:06:13,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],relieve,N/a,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:08:23,1739452297,9/16/2015 10:07:36,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],CAPSAICIN lidocaine PAIN,treat,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:09:27,1739452623,9/16/2015 10:09:13,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],relieve,n/a,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:11:53,1739453282,9/16/2015 10:11:39,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],decrease,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:29:50,1739458757,9/16/2015 10:29:30,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],decrease,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214392,9/16/2015 10:34:10,1739460138,9/16/2015 10:33:12,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",relieve,N/A,45,0,49,48,9,RO-may_prevent,820286-FS1,CAPSAICIN and the lidocaine 5% patch relieve PAIN and decrease allodynia.,PAIN,CAPSAICIN
789214393,9/16/2015 09:34:04,1739442606,9/16/2015 09:33:47,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],FDA approves THALIDOMIDE for HANSEN'S DISEASE,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 09:43:54,1739445102,9/16/2015 09:42:40,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],for,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 09:50:32,1739446607,9/16/2015 09:49:16,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[OTHER],[OTHER],for,"""is treated by"" would be a better option.",29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 09:51:14,1739446798,9/16/2015 09:51:00,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],"side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 09:55:31,1739448102,9/16/2015 09:55:21,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],approves,n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:03:26,1739450597,9/16/2015 10:02:43,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],for,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:06:33,1739451717,9/16/2015 10:06:12,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],"side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:08:39,1739452394,9/16/2015 10:07:53,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],THALIDOMIDE for HANSEN'S DISEASE,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:11:44,1739453249,9/16/2015 10:11:21,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],THALIDOMIDE for HANSEN'S DISEASE,N/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:12:50,1739453521,9/16/2015 10:12:06,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],approves,n/a,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:13:53,1739453807,9/16/2015 10:12:35,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:14:02,1739453829,9/16/2015 10:13:09,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],THALIDOMIDE HANSEN'S DISEASE,treat,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:14:55,1739454194,9/16/2015 10:14:40,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SIDE_EFFECT],[SIDE_EFFECT],"side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:32:44,1739459682,9/16/2015 10:32:28,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SIDE_EFFECT],[SIDE_EFFECT],"side effect,",N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214393,9/16/2015 10:39:08,1739461381,9/16/2015 10:36:45,false,neodev,1.0,11382239,AUS,02,Strathfield,60.241.129.81,[TREATS],[TREATS],for,N/A,29,13,45,44,24,RO-may_treat,820088-FS1,"FDA approves THALIDOMIDE for HANSEN'S DISEASE side effect, imposes unprecedented restrictions on distribution.",HANSEN'S DISEASE,THALIDOMIDE
789214394,9/16/2015 09:42:52,1739444888,9/16/2015 09:42:38,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],efficacy of,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 09:57:39,1739448665,9/16/2015 09:57:21,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:01:00,1739449816,9/16/2015 10:00:43,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],efficacy,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:16:57,1739454961,9/16/2015 10:16:38,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evidence,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:17:30,1739455175,9/16/2015 10:17:10,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:17:59,1739455321,9/16/2015 10:17:37,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],efficacy,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:20:03,1739455915,9/16/2015 10:19:17,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[LOCATION],[LOCATION],in,n/a,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:23:30,1739456955,9/16/2015 10:23:01,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:27:53,1739458162,9/16/2015 10:26:41,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],CLOMIPRAMINE OCD WITHOUT CONCOMITANT DEPRESSION effect.,treat,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:41:32,1739462127,9/16/2015 10:40:00,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:41:46,1739462207,9/16/2015 10:41:32,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:47:30,1739463878,9/16/2015 10:46:57,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],evidence of the efficacy of,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:48:04,1739464069,9/16/2015 10:47:32,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[SIDE_EFFECT],[SIDE_EFFECT],effect.,Effect,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:52:11,1739465322,9/16/2015 10:49:29,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],efficacy of,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214394,9/16/2015 10:54:23,1739465936,9/16/2015 10:53:43,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",efficacy of in,N/A,56,40,90,89,52,RO-may_treat,820121-FS1,Thirdly the evidence of the efficacy of CLOMIPRAMINE in OCD WITHOUT CONCOMITANT DEPRESSION reported by Montgomery 1980 and supported by other studies suggests that 5 HT uptake inhibitors have a specifically anti obsessional effect.,OCD WITHOUT CONCOMITANT DEPRESSION,CLOMIPRAMINE
789214395,9/16/2015 09:35:14,1739442858,9/16/2015 09:34:51,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],controlled clinical trial,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 09:47:07,1739445808,9/16/2015 09:46:48,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],clinical trial,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 09:51:46,1739446936,9/16/2015 09:51:30,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SYMPTOM],[SYMPTOM],endpoints,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 09:52:54,1739447341,9/16/2015 09:51:51,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,"A better phraseology would be ""is treated by"".",205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 09:56:14,1739448279,9/16/2015 09:56:01,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",to investigate,n/a,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:05:14,1739451243,9/16/2015 10:04:40,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],controlled clinical trial,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:08:52,1739452455,9/16/2015 10:08:03,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:09:30,1739452649,9/16/2015 10:09:04,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],ROSIGLITAZONE to investigate cardiovascular endpoints TYPE 2 DIABETES,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:13:48,1739453787,9/16/2015 10:13:15,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],trial,n/a,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:13:51,1739453797,9/16/2015 10:13:03,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],clinical trial of,N/a,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:15:25,1739454360,9/16/2015 10:14:45,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],ROSIGLITAZONE TYPE 2 DIABETES,prevent,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:16:41,1739454835,9/16/2015 10:15:19,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],cardiovascular endpoints,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:16:57,1739454966,9/16/2015 10:15:30,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:33:21,1739459830,9/16/2015 10:33:06,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],investigate,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214395,9/16/2015 10:37:41,1739461013,9/16/2015 10:36:55,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to investigate,N/A,205,134,220,219,147,RO-may_treat,820045-FS1,"Similar findings were observed in an interim analysis of fractures in another large, ongoing, long term, controlled clinical trial of ROSIGLITAZONE to investigate cardiovascular endpoints in patients with TYPE 2 DIABETES ( GlaxoSmithKline letter.",TYPE 2 DIABETES,ROSIGLITAZONE
789214396,9/16/2015 09:41:59,1739444643,9/16/2015 09:41:17,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",IN POORLY CONTROLLED NIDDM SUBJECTS primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 09:56:43,1739448412,9/16/2015 09:56:24,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PART_OF],[PART_OF],the primary,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 09:59:24,1739449269,9/16/2015 09:58:40,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],the primary,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:16:04,1739454615,9/16/2015 10:15:34,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],inhibition of hepatic glycogenolysis.,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:16:48,1739454895,9/16/2015 10:16:20,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],POORLY CONTROLLED NIDDM SUBJECTS primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:17:02,1739454990,9/16/2015 10:16:21,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[PART_OF],[PART_OF],related,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:18:57,1739455571,9/16/2015 10:18:39,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[LOCATION],[LOCATION],IN,n/a,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:22:29,1739456680,9/16/2015 10:22:14,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PART_OF],[PART_OF],the primary,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:26:08,1739457743,9/16/2015 10:25:14,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[PREVENTS],[PREVENTS],IN POORLY CONTROLLED NIDDM SUBJECTS MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL,is,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:38:01,1739461083,9/16/2015 10:36:39,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:40:41,1739461834,9/16/2015 10:39:39,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PART_OF],[PART_OF],the primary,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:46:20,1739463504,9/16/2015 10:45:51,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:46:49,1739463636,9/16/2015 10:46:17,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[CAUSES],[CAUSES],accelerated,Causes,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:47:49,1739463977,9/16/2015 10:46:41,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[CAUSES] [OTHER],"[CAUSES]
[OTHER]",primary,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214396,9/16/2015 10:59:25,1739467425,9/16/2015 10:56:40,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER] [MANIFESTATION],"[MANIFESTATION]
[OTHER]",MECHANISM,N/A,0,48,26,34,102,RO-may_treat,820122-FS1,"IN POORLY CONTROLLED NIDDM SUBJECTS the primary MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL is related to the suppression of accelerated basal HGP, and this most likely is secondary to an inhibition of hepatic glycogenolysis.",IN POORLY CONTROLLED NIDDM SUBJECTS,MECHANISM BY WHICH METFORMIN IMPROVES GLYCEMIC CONTROL
789214397,9/16/2015 09:43:09,1739444941,9/16/2015 09:42:55,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],in the treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 09:57:58,1739448786,9/16/2015 09:57:41,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:01:15,1739449902,9/16/2015 10:01:00,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:17:19,1739455116,9/16/2015 10:16:59,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:17:46,1739455255,9/16/2015 10:17:31,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],ASPIRIN treatment of chronic PAIN,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:18:17,1739455414,9/16/2015 10:18:00,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:20:17,1739455945,9/16/2015 10:20:04,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:23:48,1739457024,9/16/2015 10:23:33,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:28:48,1739458475,9/16/2015 10:27:55,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],ASPIRIN PAIN,prevent,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:42:40,1739462401,9/16/2015 10:41:33,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:42:40,1739462407,9/16/2015 10:41:49,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:48:04,1739464056,9/16/2015 10:47:31,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treatment,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:49:07,1739464380,9/16/2015 10:48:06,false,elite,1.0,34356654,USA,DE,"",108.59.11.227,[TREATS],[TREATS],treatment,Treat,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:52:46,1739465469,9/16/2015 10:52:12,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment of,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214397,9/16/2015 10:54:45,1739465996,9/16/2015 10:54:23,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,123,87,127,126,94,RO-may_prevent,820365-FS1,"Rubin P, Yee JP, Ruoff G. Comparison of long term safety of ketorolac tromethamine and ASPIRIN in the treatment of chronic PAIN",PAIN,ASPIRIN
789214398,9/16/2015 13:25:11,1739507324,9/16/2015 13:24:47,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a of is of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 13:48:06,1739516512,9/16/2015 13:47:50,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a of is of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:00:00,1739520261,9/16/2015 13:59:39,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a of is of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:12:17,1739524611,9/16/2015 14:12:03,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[TREATS],[TREATS],full course,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:13:03,1739524847,9/16/2015 14:12:44,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a of of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:23:37,1739528535,9/16/2015 14:23:09,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",of of of a of is of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:28:00,1739530046,9/16/2015 14:27:44,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",control of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:46:57,1739537177,9/16/2015 14:46:30,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[TREATS],[TREATS],GOUT full course of COLCHICINE is preferred therapy.,na,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 14:52:46,1739539417,9/16/2015 14:52:31,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],preferred method of therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 15:08:09,1739545788,9/16/2015 15:07:21,false,clixsense,1.0,32049531,USA,VA,Manassas,198.7.59.110,[NONE],[NONE],none,none,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 15:08:40,1739545981,9/16/2015 15:07:38,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[TREATS],[TREATS],administration of a full course of,N/a,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 15:09:29,1739546292,9/16/2015 15:09:03,false,instagc,1.0,22981457,CAN,ON,Ottawa,67.69.8.122,[TREATS],[TREATS],administration method of therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 15:12:31,1739547661,9/16/2015 15:11:50,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[TREATS],[TREATS],administration of a full course,n/a,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 15:17:32,1739549775,9/16/2015 15:16:50,false,prodege,1.0,34294822,USA,TX,Allen,99.7.230.126,[TREATS],[TREATS],method therapy.,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214398,9/16/2015 15:19:50,1739551243,9/16/2015 15:19:28,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,[PART_OF],[PART_OF],of,N/A,33,73,37,36,83,RO-may_prevent,820244-FS1,For control of acute episodes of GOUT administration of a full course of COLCHICINE is the preferred method of therapy.,GOUT,COLCHICINE
789214399,9/16/2015 11:11:11,1739470650,9/16/2015 11:08:55,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CONTRAINDICATES],[CONTRAINDICATES],play a role,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:24:51,1739474153,9/16/2015 11:24:37,false,neodev,1.0,33228343,USA,DE,Wilmington,199.115.115.207,[CAUSES] [PREVENTS] [TREATS] [CONTRAINDICATES] [SIDE_EFFECT] [MANIFESTATION] [LOCATION] [IS_A] [PART_OF] [OTHER] [NONE],"[TREATS]
[PREVENTS]
[CAUSES]
[LOCATION]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[IS_A]
[PART_OF]
[OTHER]
[NONE]",Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:26:18,1739474401,9/16/2015 11:25:50,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],recovery,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:31:16,1739475554,9/16/2015 11:30:56,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HYPOGLYCEMIA,none,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:49:49,1739480272,9/16/2015 11:48:39,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[OTHER],[OTHER],GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:50:16,1739480347,9/16/2015 11:49:23,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],levels,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:51:16,1739480554,9/16/2015 11:49:46,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],not in rapid recovery from,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 11:57:45,1739482015,9/16/2015 11:57:13,false,neodev,1.0,33701549,AUS,02,Sydney,103.238.131.194,[CAUSES] [CONTRAINDICATES] [ASSOCIATED_WITH] [IS_A] [NONE],"[CAUSES]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",[TREATS],N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 12:30:52,1739489819,9/16/2015 12:30:22,false,neodev,1.0,21515166,NLD,11,Nieuwkoop,83.84.200.25,[SYMPTOM],[SYMPTOM],play a role,n/a,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 12:40:38,1739492708,9/16/2015 12:40:07,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],play a role in,n/a,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 12:47:38,1739495113,9/16/2015 12:47:20,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[IS_A],[IS_A],a,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 12:55:04,1739497497,9/16/2015 12:54:31,false,neodev,1.0,20233773,GBR,H9,London,193.109.199.200,[TREATS],[TREATS],in maintaining GLUCOSE but not in rapid recovery from HYPOGLYCEMIA,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 13:03:10,1739499921,9/16/2015 13:02:53,false,neodev,1,30321275,USA,NV,Las Vegas,192.30.80.4,[IS_A],[IS_A],a,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 13:10:44,1739502673,9/16/2015 13:10:12,false,elite,1,28548715,USA,"","",38.95.109.38,[SYMPTOM],[SYMPTOM],Cortisol growth hormone,n/a,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214399,9/16/2015 13:13:07,1739503531,9/16/2015 13:11:29,false,fusioncash,1,21457135,USA,FL,Orlando,71.42.61.239,[CAUSES],[CAUSES],GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,N/A,151,105,163,162,112,RO-may_treat,820003-FS1,Cortisol and growth hormone are also secreted in response to hypoglycemia and play a role in maintaining GLUCOSE levels but not in rapid recovery from HYPOGLYCEMIA,HYPOGLYCEMIA,GLUCOSE
789214400,9/16/2015 12:56:21,1739497917,9/16/2015 12:56:06,false,neodev,1.0,32695853,USA,NV,Las Vegas,192.30.80.172,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug DRUGS,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 13:09:52,1739502438,9/16/2015 13:09:21,false,neodev,1.0,30321275,USA,NV,Las Vegas,192.30.80.4,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug DRUGS,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 13:16:52,1739504834,9/16/2015 13:16:33,false,elite,1.0,28548715,USA,"","",38.95.109.38,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],noninvasive drug studies involving,n/a,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 13:20:09,1739505799,9/16/2015 13:19:56,false,neodev,1.0,31329809,USA,DE,Wilmington,162.223.93.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug DRUGS,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 13:42:48,1739514766,9/16/2015 13:42:29,false,neodev,1.0,33018272,USA,DE,Wilmington,162.223.93.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug DRUGS,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 13:54:29,1739518411,9/16/2015 13:54:17,false,neodev,1.0,30941227,USA,NV,Las Vegas,192.30.80.166,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:07:25,1739522765,9/16/2015 14:06:51,false,clixsense,1.0,6340330,USA,NY,Canajoharie,67.248.115.74,[PART_OF],[PART_OF],ANTIARRHYTHMIC DRUGS ARRHYTHMIA,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:07:40,1739522871,9/16/2015 14:07:23,false,neodev,1.0,29363385,USA,DE,Wilmington,162.223.93.162,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug DRUGS,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:08:57,1739523446,9/16/2015 14:07:38,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [SIDE_EFFECT] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]","In 1,287 drug studies 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 (9%.",n/a,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:15:57,1739525846,9/16/2015 14:13:12,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[CAUSES],[CAUSES],aggravation occurred,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:18:30,1739526676,9/16/2015 14:18:12,false,neodev,1.0,33435788,USA,DE,Wilmington,162.223.93.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],drug DRUGS,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:33:30,1739532020,9/16/2015 14:31:58,false,neodev,1.0,23017572,USA,CA,Santa Ana,67.215.241.20,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]","over 1,287 noninvasive drug studies aggravation occurred in 117 tests",n/a,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:40:47,1739534802,9/16/2015 14:40:24,false,neodev,1.0,18881135,CAN,ON,Ajax,99.243.87.224,[CAUSES],[CAUSES],ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation,na,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:48:28,1739537766,9/16/2015 14:48:05,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],aggravation occurred,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214400,9/16/2015 14:50:35,1739538655,9/16/2015 14:48:47,false,neodev,1.0,32499893,USA,CA,San Jose,173.245.65.56,[CAUSES],[CAUSES],ANTIARRHYTHMIC DRUGS ARRHYTHMIA,N/A,73,52,84,82,72,RO-may_prevent,820323-FS1,"In over 1,287 noninvasive drug studies involving 11 ANTIARRHYTHMIC DRUGS ARRHYTHMIA aggravation occurred in 117 tests (9%.",ARRHYTHMIA,ANTIARRHYTHMIC DRUGS
789214401,9/16/2015 09:34:50,1739442793,9/16/2015 09:34:05,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cost effectiveness vaccination,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 09:46:48,1739445708,9/16/2015 09:43:54,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,Checking cost effectiveness,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 09:51:29,1739446888,9/16/2015 09:51:15,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],infections,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 09:51:46,1739446938,9/16/2015 09:50:34,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/A,The terms are not related in this sentence.,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 09:56:00,1739448191,9/16/2015 09:55:32,false,clixsense,1,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC HEPATITIS HEPATITIS,n/a,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:04:39,1739451042,9/16/2015 10:03:27,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH] [IS_A],"[ASSOCIATED_WITH]
[IS_A]",and,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:07:10,1739451934,9/16/2015 10:06:35,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],Preventing,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:09:02,1739452505,9/16/2015 10:08:40,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC HEPATITIS C immunization HEPATITIS A,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:13:02,1739453543,9/16/2015 10:11:45,false,prodege,1.0,22031444,GBR,F2,Gosport,92.24.223.243,[NONE],[NONE],N/a,No relation indicated between the two terms.,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:13:14,1739453636,9/16/2015 10:12:52,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:14:44,1739454091,9/16/2015 10:14:04,false,neodev,1.0,33644825,USA,FL,Fort Lauderdale,65.111.173.161,[TREATS],[TREATS],CHRONIC HEPATITIS C HEPATITIS,prevent,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:15:17,1739454328,9/16/2015 10:14:58,false,elite,1.0,30659754,USA,"","",162.250.145.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],vaccination,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:15:29,1739454383,9/16/2015 10:13:54,false,neodev,1.0,30581619,USA,CA,Laguna Niguel,216.177.129.147,[NONE],[NONE],good,good,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:33:03,1739459755,9/16/2015 10:32:46,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],vaccination,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
789214401,9/16/2015 10:38:26,1739461179,9/16/2015 10:36:51,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",Association Incidence,N/A,189,384,206,207,395,RO-may_prevent,820368-FS1,"Infectious Diseases  Preventing hepatitis A and hepatitis B virus infections among men who have sex with men  Hepatology  The cost effectiveness of hepatitis A vaccination in patients with CHRONIC HEPATITIS C  Journal of the American Medical Association  Incidence of hepatitis A in Israel following universal immunization of toddlers  New England Journal of Medicine  An outbreak of HEPATITIS A associated with green onions  Vaccine  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix B) in adults  Review  Clinical Microbiology Reviews  Hepatitis A:.",CHRONIC HEPATITIS C,HEPATITIS A
